NEWS
Advancements in Patient-Centered Care
Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.
Minnesota Oncology First to Earn NCODA Center of Excellence Medically-Integrated Pharmacy Accreditation
May 12, 2022 |
. MEDIA CONTACTS: Katie Edmiston | Marketing Manager | NCODA Katie.Edmiston@ncoda.org 813-843-1629 Courtney Anderson | Director, Mktg & Patient Growth | Minnesota Oncology Courtney.Anderson@usoncology.com 612-309-3415 Minnesota Oncology First to Earn NCODA Center of Excellence Medically-Integrated Pharmacy Accreditation CAZENOVIA, NY – May 12, 2022 – Minnesota Oncology has become the first […]
read more
MAINE PUSHES FORWARD WITH COPAY REFORM
May 6, 2022 |
May 6, 2022 FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org MAINE PUSHES FORWARD WITH COPAY REFORM Copay accumulator reform has been sweeping the nation so far this year. We are thrilled that the state of […]
read more
WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS
April 20, 2022 |
April 20, 2022 FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS The state of Washington wrapped up their legislative session with a huge victory for patients. Senate […]
read more
NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options
April 14, 2022 |
NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options “NCODA Informatics Initiative Powered by VisualStrata” Helps Attract Clinical Trials for Oncology Practices and Bridges the Gap with Pharmaceutical Organizations San Diego, CA and Cazenovia, NY April 14, 2022 – XIFIN has partnered with NCODA, Inc., a globally recognized association that develops unique […]
read more
OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS
April 6, 2022 |
FOR IMMEDIATE RELEASE April 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS CAZENOVIA, NY – NCODA is proud to share the news that the Ohio House unanimously (86 to 0) […]
read more
NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians
March 29, 2022 |
FOR IMMEDIATE RELEASE March 29, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@NCODA.org 813-843-1629 NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians CAZENOVIA, NY – NCODA, a professional association dedicated to empowering the medically-integrated oncology community through leadership, quality standards, and best practices, is now certified by the Accreditation Council for […]
read more
Oral Oncolytic Non-Adherence in Medically Integrated Dispensing Pharmacies
March 24, 2022 |
The challenges associated with medication adherence and the negative impacts of non-adherence have been well documented. Medication adherence affects many aspects of public health, including, but not limited to, quality of life, patient outcomes, and overall healthcare costs.1 It is generally accepted that adherence rates of more than 80% are needed for optimal therapeutic efficacy.2 […]
read more
Oral Oncolytic Care Plans in Medically Integrated Dispensing Pharmacies
March 24, 2022 |
The development and utilization of oral oncolytics has steadily increased over the past 20 years. There are over 800 new oncology therapies in the drug development pipeline, 25%-35% of which are oral agents.1 The use of oral oncolytics presents unique challenges to patient safety compared to intravenous cancer treatments. As oral oncolytics are self-administered, it […]
read more
First-Of-Its-Kind Oncology State Legislation Tracking Tool
March 15, 2022 |
FOR IMMEDIATE RELEASE March 15, 2022 MEDIA CONTACT: Stephen Ziter Stephen.Ziter@ncoda.com 518-867-5001 First-Of-Its-Kind Oncology State Legislation Tracking Tool NCODA Launches a New Comprehensive Resource to Allow Oncology Healthcare Professionals to Stay Updated on the Latest in Relevant Policy/Legislation in all 50 States CAZENOVIA, NY – Today, NCODA announces the launch of its new and […]
read more
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
March 1, 2022 |
– VONJO is the First Approved Therapy to Specifically Address the Needs of Adult Cytopenic Myelofibrosis Patients – NDA Approved Under Priority Review – Approval Triggers $60 Million Payment from DRI Healthcare Trust – CTI to Host Conference Call Tomorrow at 8:00 a.m. ET SEATTLE, Feb. 28, 2022 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. […]
read more
Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients
February 25, 2022 |
FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients On February 24, 2022, the Federal Trade Commission (FTC) announced that they are soliciting public input on the […]
read more
PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES
February 25, 2022 |
FOR IMMEDIATE RELEASE STATEMENT FROM NCODA’S LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES In recent weeks, NCODA has been closely following and applauding PBM reform along with new provisions regarding patient copayments. […]
read more
OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP
February 18, 2022 |
February 18, 2022 FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP A Comprehensive PBM Reform Bill is on the Desk of Michigan Gov. Gretchen Whitmer Awaiting […]
read more
NCODA Stands United With Biden Administration On Cancer Moonshot
February 17, 2022 |
Contact: Katie Edmiston | Marketing Manager NCODA, Inc. (813) 843-1629 Katie.Edmiston@ncoda.org February 17, 2022 NCODA Stands United with Biden Administration on Cancer Moonshot (CAZENOVIA, NY) – NCODA has always been committed to empowering the medically integrated oncology team to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards and best practices. […]
read more
Neratinib (Nerlynx®) Diarrhea Management
February 16, 2022 |
Written by: Eric Dallara, RPh, New England Cancer Specialist Download Here Description: Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the neratinib arm in which antidiarrheal prophylaxis was not protocol specified.1 Various prevention and treatment strategies for diarrhea have been studied and will be discussed […]
read more
New NDC number for TIBSOVO®
February 15, 2022 |
Beginning February 14, 2022, there is a new NDC number for TIBSOVO® (72694-0617-60)*, the old NDC number was 71334-0100-01. SERVIER has new product packaging. The product itself remains the same. Listed below are pictures of the updated product packaging and ordering information. Updated Product Ordering Information: Description Strength/Size Supplier New NDC # TIBSOVO® (ivosidenib tablets) 250 mg tablet […]
read more
Fam-Trastuzumab deruxtecan-nxki (Enhertu®) Management
February 4, 2022 |
Written by: Brandy Persson, PharmD, BCPS, BCOP and Rebecca Fanning, PharmD, BCPS, Cone Health Download Here Description: Fam-trastuzumab deruxtecan-nxki is indicated for the treatment of: Adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with two or more anti-HER2-based regimens.1,2 This indication is under accelerated approval based […]
read more
Durvalumab (Imfinzi®) Therapy Overview
February 4, 2022 |
Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss the overall management of durvalumab and immune-mediated adverse events in the treatment of Stage III unresectable NSCLC and first-line extensive stage small cell lung cancer. Background: Durvalumab is a PD-L1 blocking monoclonal antibody and immune checkpoint inhibitor indicated […]
read more
Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia and Follicular Lymphoma
February 1, 2022 |
Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers Download Here Description: The purpose of this PQI is to provide background on PI3K inhibition and review clinical considerations for duvelisib therapy in order to optimize outcomes for cancer patients as well as identifying the patients with malignant lymphoma who may be candidates for duvelisib. […]
read more
Selinexor (Xpovio®) Patient Management
February 1, 2022 |
Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center Download Here Description: This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to […]
read more
Use of Isatuximab-irfc (Sarclisa®) in Patients with Relapsed Refractory Multiple Myeloma
January 28, 2022 |
Written by: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch Download Here Description: The purpose of this PQI is to discuss the option of using isatuximab-irfc (Sarclisa) for multiple myeloma patients who have been refractory to one to three prior lines of therapy or have had two prior treatment therapies including treatment with lenalidomide and a […]
read more
Tivozanib (Fotivda®) for Relapsed or Refractory Advanced Renal Cell Carcinoma
January 18, 2022 |
Written By: Pedro C. Barata, MD, Tulane University DOWNLOAD HERE Description: The purpose of this PQI is to review the clinical considerations around the use of tivozanib (Fotivda®) for patients with relapse or refractory advanced renal cell carcinoma. Background: Tivozanib is a small molecule that inhibits the phosphorylation of vascular endothelial growth factor […]
read more
Enfortumab Vedotin-ejfv (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma
January 14, 2022 |
Written by: Andrew Ruplin, PharmD, Seattle Cancer Care Alliance Download Here The purpose of this PQI is to understand the management techniques and interventions when utilizing enfortumab vedotin.
read more
NCODA Welcomes New Executive Council Members
January 12, 2022 |
FOR IMMEDIATE RELEASE January 12, 2022 Contact: Katie Edmiston | Marketing Manager (813) 843-1629 Katie.Edmiston@ncoda.org NCODA WELCOMES NEW EXECUTIVE COUNCIL MEMBERS CAZENOVIA, NY – NCODA today announced the appointment of four new members to the Executive Council. With the growth of NCODA, the Executive Council has been instrumental in facilitating a strong path forward […]
read more
Temozolomide (Temodar®) for Glioblastoma Multiforme
January 4, 2022 |
Written By: Hassaan Shaikh, PharmD & Emily Brugioni, MD, University Health DOWNLOAD HERE Description: The purpose of this PQI is a summary of the process for initiating and monitoring oral temozolomide therapy in patients with Glioblastoma Multiforme (GBM). Background: GBM is the most common primary malignant brain tumor in adults and comprises 54 % of […]
read more
GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS
January 3, 2022 |
FOR IMMEDIATE RELEASE January 3rd 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS Throughout 2021 NCODA highlighted states throughout the country that took great strides to regulate Pharmacy […]
read more
Ponatinib (Iclusig®) Patient Management
December 20, 2021 |
Written by: Jessie Signorelli PharmD, BCOP, Massachusetts General Hospital DOWNLAD HERE Description: This PQI will aim to review ponatinib efficacy and safety data as well as clinical pearls regarding supportive care and adverse event management.1 Background: Ponatinib (Iclusig®) is a third-generation tyrosine kinase inhibitor (TKI) with activity directed at BCR-ABL mutant kinase in patients with […]
read more
Managing EGFR Inhibitor Induced Rash
December 13, 2021 |
Written by: Sara Moran Smith, PharmD, BCOP | M Health Fairview DOWNLOAD HERE Purpose: Rash occurs in approximately 90% of patients treated with epidermal growth factor receptor (EGFR) inhibitors1 with 10-20% developing severe eruption.1 Studies have shown that the presence of this rash is indicative of response to treatment.1 Therefore, it is important to prevent […]
read more
DPYD Testing Prior to Fluoropyrimidine Treatment
December 13, 2021 |
Written by: Dan Hertz, PharmD, PhD – University of Michigan College of Pharmacy DOWNLOAD HERE Description: The purpose of this PQI is to review recommendations for DPYD testing prior to initiation of treatment with fluoropyrimidine based chemotherapy and increase awareness of the clinical benefit of pre-treatment DPYD testing. Background: Fluoropyrimidine (5-fluorouracil or capecitabine) chemotherapy is […]
read more
FGFR Inhibitor Side Effect Management
November 23, 2021 |
Written By: Julia Stevens, PharmD, BCOP and Emmeline Academia, PharmD, BCOP – Beth Israel Deaconess Medical Center DOWNLOAD HERE Description: Fibroblast growth factor receptor (FGFR) inhibitors are a class of oral oncolytics approved for certain FGFR-altered malignancies, including bladder cancer (erdafitinib) and cholangiocarcinoma (infigratinib and pemigatinib). FGFR inhibitors come with unique adverse effect profiles and […]
read more
Regorafenib (Stivarga®) in Metastatic Colorectal Cancer
November 22, 2021 |
Written By: Neal Dave, PharmD, and Natasha Khrystolubova, RPh, BCOP Download Here Description: Management of adverse effects related to regorafenib treatment in metastatic colorectal cancer. Optimal dosing and follow up are essential to help patients benefit fully while taking this medication. Background: Regorafenib is a multikinase inhibitor that has shown an overall survival benefit (6.4 […]
read more
Comment On Proposed LCD DL37810
November 12, 2021 |
November 12, 2021 Statement From NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org FOR IMMEDIATE RELEASE Comment On Proposed LCD DL37810 Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms: Optimizing Management of Patients in Underserved and Minority Populations CAZENOVIA, […]
read more
Vaccination for Non-Transplant Patients with Cancer
November 10, 2021 |
Written by: Michelle Hoa and Natasha Heimbigner, PharmD – Summit Cancer Centers Download Here Description: Patients undergoing cancer treatment are more susceptible to infections due to their compromised immune system. This PQI will review which vaccinations cancer patients can or cannot use for the proper protection against preventable infections. Background: Cancer treatments weaken the immune […]
read more
Mobocertinib (Exkivity™) Side Effect Management
November 8, 2021 |
Written by: Danny Nguyen, MD, Nishan Tchekmedyian, MD, André K.D. Liem, MD, City of Hope National Medical Center DOWNLOAD HERE Description: Mobocertinib (Exkivity™) is an oral EGFR tyrosine kinase inhibitor (TKI) designed to specifically target EGFR ex20ins mutations.1 This PQI will discuss effective strategies for side effect management. Background: Mobocertinib is indicated in locally advanced or […]
read more
Use of Belumosudil (Rezurock®) for the Treatment of Chronic Graft-Versus-Host Disease
November 5, 2021 |
Written by: Megan Dillaman, PharmD, BCOP DOWNLOAD HERE Description: The purpose of this PQI is to discuss the use of belumosudil (Rezurock®) in the management of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation. Belumosudil was approved by the United States Food & Drug Administration (FDA) in 2021 with indication for use in patients […]
read more
Fostamatinib (Tavalisse®) Use in Chronic Immune Thrombocytopenia
November 4, 2021 |
Written by: Julianna Darling, PharmD, Indiana University Health Simon Cancer Center Download Here Positive Quality Intervention: Fostamatinib (Tavalisse) use in Chronic Immune Thrombocytopenia Description: Fostamatinib is an oral spleen tyrosine kinase (Syk) inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a […]
read more
Patients Are The Priority: A Call For A Medically Integrated Community
October 28, 2021 |
Contact: Kevin Scorsone NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org Statement From NCODA Legislative & Policy Advisory Committee October 28, 2021 Patients Are The Priority: A Call For A Medically Integrated Community CAZENOVIA, NY – New York State is the home of NCODA, and at one time locally owned pharmacies were commonplace. But […]
read more
Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer
October 28, 2021 |
Written by: Alyson Leonard, PharmD, BCPS, BCOP Cone Health Download Here Description: Cabazitaxel is indicated for treatment of patients with metastatic castration-resistant prostate (mCRPC) cancer previously treated with a docetaxel-containing treatment regimen in combination with prednisone.1 The purpose of this PQI is to provide guidance for initiating cabazitaxel. Background: Cabazitaxel was FDA approved in 2010 […]
read more
Sorafenib (Nexavar) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)
October 28, 2021 |
Written by: Jeff Engle, PharmD, MS Download Here Description: This PQI will discuss effective management of adverse effects of sorafenib in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit. Background: Hepatocellular carcinoma (HCC) is associated with a high mortality rate […]
read more
Management of Abemaciclib (Verzenio®) Associated Diarrhea
October 28, 2021 |
Written by: Derek Gyori, PharmD and Julianne Orr, PharmD Download Here Description: Abemaciclib is FDA-approved in combination with an aromatase inhibitor, fulvestrant, and as a single agent in early high-risk, advanced, or metastatic breast cancer. This PQI will address effective practices for the management of abemaciclib associated diarrhea, a common toxicity with this therapy. Background: Abemaciclib […]
read more
Advanced Breast Cancer: Appropriate Patient Identification with Abemaciclib (Verzenio®)
October 28, 2021 |
Written by: Jan Montgomery, PharmD, South Carolina Oncology Associates and Jacob Dygert, South University School of Pharmacy Download Here Description: To identify appropriate eligible patients for abemaciclib therapy based upon specific prognostic factors. Background: Abemaciclib is indicated for the treatment of postmenopausal women with HR-Positive, HER2- Negative in early high-risk, advanced, or metastatic breast cancer. […]
read more
Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation
October 19, 2021 |
Media Contacts: Jenine Anderson│Public Relations Manager Jenine.Anderson@primetherapeutics.com Suzi Baugh│850-545-4247 Suzi@sachsmedia.com Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation Accredited medically integrated pharmacies may become eligible to participate in Prime’s IntegratedRx™ – Oncology network EAGAN, Minn. and CAZENOVIA, NY– Oct. 19, 2021 – […]
read more
A Win For Cancer Patients: First-of-Its-Kind Collaboration Between National Oncology Pharmacy Nonprofit and PBM
October 18, 2021 |
FOR IMMEDIATE RELEASE MEDIA CONTACT: October 18, 2021 Suzi Baugh Suzi@sachsmedia.com 850-545-4247 A Win For Cancer Patients: First-of-Its-Kind Collaboration Between National Oncology Pharmacy Nonprofit and PBM NCODA’s medically integrated pharmacy accreditation creates gold standard for oncology practices dispensing medication to patients, from first to last fill CAZENOVIA, NY – NCODA, an organization dedicated to providing […]
read more
Advanced Systemic Mastocytosis Patient Diagnostic Algorithm
October 13, 2021 |
Written by: Prithviraj Bose, MD, UT MD Anderson Cancer Center DOWNLOAD HERE Description: The purpose of this PQI is to assist in the diagnosis of the advanced systemic mastocytosis patient by providing a diagnostic algorithm. Background: Systemic mastocytosis (SM) is a myeloid neoplasm driven in ~95% of cases by an activating mutation, D816V, affecting exon […]
read more
Selpercatinib (Retevmo®) Management
October 12, 2021 |
Written By: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI is developed to provide guidance for management of patients treated with selpercatinib. Background: Selpercatinib is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RETfusion-positive non-small cell lung cancer (NSCLC) Adult and pediatric patients 12 years of age and older with advanced […]
read more
Trifluridine and Tipiracil (Lonsurf®) for Treatment of Gastric Cancer
October 12, 2021 |
Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute Download Here Description: This PQI will review patient identification and clinical considerations for this treatment option for gastric cancer. Background: Trifluridine and Tipiracil is approved for use in patients with gastric or gastroesophageal junction (GEJ) cancer who have failed at least two prior lines of […]
read more
Bortezomib (Velcade) Management for Multiple Myeloma and Mantle Cell Lymphoma
October 12, 2021 |
Written By: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss the option of using bortezomib for multiple myeloma (MM) and mantle cell lymphoma (MCL) patients. Background: Bortezomib is a reversible proteasome inhibitor of the chymotrypsin-like activity of the 26S proteasome and is approved for treatment of adult patients […]
read more
Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma
October 8, 2021 |
Written by: Jody Agena, PharmD, Virginia Cancer Specialists Download Here Description: Understand how to identify eligible patients and manage adverse effects of regorafenib treatment in hepatocellular carcinoma. Background: Regorafenib is a kinase inhibitor indicated for the treatment of patients (Childs Pugh A) with Hepatocellular Carcinoma (HCC) who have been previously treated with sorafenib. In the […]
read more
Niraparib (Zejula): Dose Modifications Based on Weight and Platelet Counts
October 8, 2021 |
Written by: Michelle Phillips, PharmD, University of Rochester Medical Center Download Here Description: The purpose of this PQI is to highlight key criteria for appropriate monitoring, dosing, and administration to improve the dispensing and management of patients taking niraparib (Zejula). Background: Niraparib is indicated for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian […]
read more
Selpercatinib (Retevmo®) Genomic Testing Management
October 8, 2021 |
Written By: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI is developed to provide guidance to genomic testing with respect to selpercatinib. Background: RET-altered cancers include both RET fusions and RET mutations. Both alterations involve activating RET signaling pathways that promote unwanted cell proliferation in cancers. NCCN guidelines for NSCLC include a Category 2A […]
read more
Larotrectinib (Vitrakvi®) Overview
October 8, 2021 |
Written By: Elizabeth Ledbetter, PharmD DOWNLOAD HERE Description: The purpose of this PQI is to help provide awareness of larotrectinib and educate on management techniques. Background: Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that: Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance […]
read more
Avapritinib (Ayvakit®) Management for Gastrointestinal Stromal Tumor
October 7, 2021 |
Written By: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI will discuss the initiation and management of patients receiving avapritinib. Background: Avapritinib is a tyrosine kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. […]
read more
Ruxolitinib (Jakafi®) in the Treatment of Polycythemia Vera
October 7, 2021 |
Written by Neal Dave, PharmD, Texas Oncology Download Here Description: This PQI will review appropriate patient identification and management of Polycythemia Vera (PV) with the use of ruxolitinib therapy. Background: Common treatments for PV are aspirin, phlebotomy, hydroxyurea, interferon (not commonly used), or a JAK2 inhibitor, ruxolitinib. Hydroxyurea (HU) is considered the gold standard treatment […]
read more
Gilteritinib (Xospata®) for Relapsed/Refractory Acute Myeloid Leukemia
October 7, 2021 |
Written by: Bryan J. Brinda, PharmD Download Here Description: This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Optimal patient identification, dosing, and follow-up […]
read more
Ibrutinib (Imbruvica®) Expansion with Obinutuzumab (Gazyva®)
October 5, 2021 |
Written by: Tammy McClellan, PharmD Download Here Description: The purpose of this PQI is to expand on therapy management of ibrutinib when used in combination with obinutuzumab. Background: This FDA has extended the indications for ibrutinib; already approved as a single agent OR in combination with bendamustine and rituximab. Ibrutinib is indicated for Mantle Cell […]
read more
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
October 5, 2021 |
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer – FDA approval based on phase 3 COSMIC-311 pivotal trial, which demonstrated significant improvement in progression-free survival with CABOMETYX versus placebo – – Exelixis is prepared to fully support expanded indication immediately – – Application approved well ahead of […]
read more
Ripretinib (Qinlock®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors
October 4, 2021 |
Written by: Joseph Bubalo PharmD, Oregon Health & Science University DOWNLOAD HERE Description: The purpose of this PQI is to summarize the process for initiating and monitoring ripretinib therapy in patients with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior kinase inhibitors including imatinib. Background: Ripretinib is a tyrosine kinase inhibitor […]
read more
Ovarian Cancer: PARP Inhibitor Eligibility
October 1, 2021 |
Written by: Martina Fraga, PharmD Download Here Description: The purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate. Background: In gynecologic cancer patients, PARP inhibitors (PARP-I), have shown increased progression free survival (PFS) and, in some cases, overall survival. Misconceptions may […]
read more
Pralsetinib (Gavreto®) Management for Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
October 1, 2021 |
Written By: Kayla Randle, PharmD, BCOP Download Here Description: Pralsetinib is an oral Rearranged during Transfection (RET) tyrosine kinase inhibitor (TKI) that inhibits oncogenic RET fusions and mutations.1 The purpose of this PQI is to review pralsetinib’s role in therapy, management of adverse effects and potential drug interactions, and to recommend patient follow up associated […]
read more
Managing Immunotherapy Treatment Related Rash
September 29, 2021 |
Written by: Natasha Heimbigner, PharmD, Summit Cancer Centers Download Here Description of PQI: The use of immunotherapy in cancer treatment has expanded tremendously over the last several years. The most common adverse effects include dermatologic, gastrointestinal, hepatic, and endocrine toxicities. Management of immunotherapy-related rash is an important intervention for the patient’s quality of life and […]
read more
Trifluridine and Tipiracil (Lonsurf®) for Metastatic Colorectal Cancer
September 29, 2021 |
Written by Jennifer M. Hasiak O’Doherty, PharmD, Hematology Oncology Consultants, PC Download Here Description: This PQI will highlight strategies for appropriate dosing and management of adverse effects related to trifluridine and tipiracil treatment in metastatic colorectal cancer. Background: Trifluridine and Tipiracil is indicated for the treatment of patients with metastatic colorectal cancer who have been […]
read more
Copanlisib (Aliqopa™) for the Management of Relapsed/Refractory Follicular Lymphoma
September 28, 2021 |
Written by: Andrew Kowalski, PharmD and Osama Abdelghany, PharmD, MHA, BCOP -Smilow Cancer Hospital at Yale New Haven HealthDownload Here Description: There are a number of treatment options for patients with follicular lymphoma that has relapsed or is refractory to first line options. The purpose of this PQI is to discuss appropriate patient identification and […]
read more
Tucatinib (Tukysa®) Management
September 28, 2021 |
Written by: Katie Carter, PharmD, BCPS, IU Simon Cancer Center Download Here Description: The purpose of this PQI is to highlight tucatinib and its usage and management in advanced unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting. Background: Tucatinib is an oral tyrosine kinase […]
read more
Avapritinib (Ayvakit®) Management for Advanced Systemic Mastocytosis
September 27, 2021 |
Written By: Andrew Kuykendall, MD; Katherine Tobon, PharmD, BCOP; Syeda Saba Kareem PharmD, BCOP Moffitt Cancer Center DOWNLOAD HERE Description: This PQI will discuss the initiation and management of patients receiving avapritinib for Advanced Systemic Mastocytosis Background: Avapritinib is a potent tyrosine kinase inhibitor that targets platelet-derived growth factor receptor alpha (PDGFRA) and KIT exon […]
read more
Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies
September 27, 2021 |
Written by: Yonatan Resnick, PharmD, New England Cancer Specialists Download Here Description: This PQI will discuss the development and rationale of the oral DNMT/CDA inhibitor for the management of intermediate-1, intermediate-2, and high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Background: Decitabine/cedazuridine is a fixed-dose combination of the hypomethylating agent decitabine and the cytidine […]
read more
Daratumumab (Darzalex®) for Multiple Myeloma
September 27, 2021 |
Written by: Lauren Trisler, PharmD, BCOP – Carle Cancer Center Download Here Description: Daratumumab injection is an anti-CD38 monoclonal antibody (mAb) FDA approved for use in a range of multiple myeloma patients including first line, transplant ineligible and relapse/refractory.1 The subcutaneous formulation (DARZALEX FASPRO®) is not indicated for front-line transplant eligible patients but is indicated for […]
read more
Larotrectinib (Vitrakvi®) Genomic Testing Management
September 23, 2021 |
Written by: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI is developed to provide guidance to genomic testing with respect to larotrectinib. Background: Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that: Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation […]
read more
Acalabrutinib (Calquence®) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
September 23, 2021 |
Written by: Trey McNiel, PharmD, Georgia Cancer Specialists Download Here Description: The purpose of this PQI is to discuss the clinical considerations around the use of acalabrutinib (Calquence®) to optimize the outcomes for patients with CLL/SLL. Background: Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor initially indicated for mantle cell lymphoma (MCL) patients who have […]
read more
Osimertinib (Tagrisso®) in EGFR Positive Non-Small Cell Lung Cancer
September 23, 2021 |
Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health Download Here Description: Osimertinib is an indicated and preferred first line treatment option for patients with Epidermal Growth Factor Receptor (EGFR) gene mutation positive Non-Small Cell Lung Cancer (NSCLC) with Exon 19 deletion or exon 21 L858R and with EGFR T790M mutation positive disease with progression on/after EGFR tyrosine kinase inhibitor- based […]
read more
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
September 22, 2021 |
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC Approval based on Phase 1/2 trial results, which demonstrated clinically meaningful responses with a median duration of response (DoR) of approximately 1.5 years Next-generation sequencing (NGS) companion diagnostic test approved simultaneously to support identification […]
read more
Non-Small Cell Lung Cancer Stage III Overview and Patient Eligibility of Durvalumab (Imfinzi®)
September 22, 2021 |
Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss Stage III Non-small cell lung cancer (NSCLC) and patient eligibility. Background: Within the category of Lung Cancer, approximately 80% to 85% of lung cancers are NSCLC.3,5 Treatment for stage III NSCLC may include combinations of radiation, chemotherapy, and/or […]
read more
Ruxolitinib (Jakafi®) in the Management of Myelofibrosis Patients
September 22, 2021 |
Written By: Todd Murphree, PharmD Clearview Cancer Institute Download Here Description of PQI: Ruxolitinib is a selective Jak2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy. Background: Ruxolitinib is FDA approved for the treatment […]
read more
Copanlisib (Aliqopa™) Toxicity Management
September 21, 2021 |
Written by: Lauren Held, PharmD, BCOP – Seattle Cancer Care Alliance Download Here Copanlisib is an intravenous (IV) phosphatidylinositol 3-kinase (PI3K) inhibitor indicated for the treatment of relapsed follicular lymphoma (FL) in patients that have received at least two prior systemic therapies.1 This PQI will review how to manage select toxicities associated with copanlisib.
read more
Afatinib (Gilotrif®) Management for Non-Small Cell Lung Cancer
September 21, 2021 |
Written By: Chris Sellers, RPh, Texas Oncology Download Here Description: The purpose of this PQI is to provide information on the management of common adverse events, follow-up with patients, and dose modifications. Dose adjustments are common and greatly reduced frequency and severity of adverse reactions. In Lux-Lung 3, 43% maintained the 40 mg starting dose, […]
read more
Zanubrutinib (Brukinsa®) Patient Selection and Management in Mantle Cell Lymphoma
September 20, 2021 |
Written by: Kayla Randle, PharmD, BCPS, BCOP, Kaiser Permanente Georgia Oncology Download Here Description: The purpose of this PQI is to identify differentiating characteristics which would indicate zanubrutinib as a preferred treatment option in Mantle Cell Lymphoma as well as discussing key counseling and monitoring criteria to improve patient outcomes. Background: Zanubrutinib is a potent, highly specific, and […]
read more
Chemotherapy Induced Nausea and Vomiting
September 16, 2021 |
Written by: Kirollos S. Hanna, PharmD, BCPS, BCOP – University of Minnesota Medical Center & Mayo Clinic Download Here Description: This PQI will discuss optimal prevention and control of chemotherapy induced nausea and vomiting (CINV) which has been associated with improved adherence to oncolytic therapy. Background: CINV remains one of the most debilitating toxicities associated […]
read more
Management of Alpelisib (Piqray®) Induced Hyperglycemia
September 16, 2021 |
Written By: Natasha Khrystolubova, RPh, BCOP, Florida Cancer Specialists and Jody Agena, PharmD, Virginia Cancer Specialists Download Here This PQI is intended to address effective practices for the management of alpelisib induced hyperglycemia by focusing on a multidisciplinary approach. Background: Alpelisib (in combination with fulvestrant) is indicated for the treatment of HR-positive, HER2-negative, PIK3CA-mutated, advanced […]
read more
Oral Chemotherapy Induced Peripheral Neuropathy
September 16, 2021 |
Written by: Andrea Clarke, PharmD and Becky Fahrenbruch, PharmD, BCOP Download Here Description: Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect that can occur with chemotherapeutics, including certain oral chemotherapy agents. Appropriate patient education and monitoring may assist with identifying early signs of peripheral neuropathy, but no agents have demonstrated efficacy in preventing CIPN. […]
read more
Olanzapine (Zyprexa) in Chemotherapy Induced Nausea and Vomiting
September 16, 2021 |
Written by Julianne Orr, PharmD, Indiana University Health Simon Cancer Center Download Here Description: Olanzapine is an FDA approved atypical antipsychotic that blocks multiple neuronal receptors involved in nausea/vomiting pathways.1 Olanzapine has been studied for breakthrough2 chemotherapy induced nausea and vomiting (CINV) as well as prophylaxis of highly and moderately emetogenic regimens.3,4,5 Additionally, olanzapine has […]
read more
Patient Screening for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
September 16, 2021 |
Written by: Tammy McClellan, PharmD, Riverside Healthcare Download Here Description: The purpose of this PQI is to assess the individualized characteristics of the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patient and important screening measures in order to achieve optimal pharmacological therapy. Background: CLL/SLL, a type of non-Hodgkin Lymphoma, is an indolent cancer in which immature […]
read more
Ixazomib (Ninlaro®) in the Treatment of Multiple Myeloma
September 16, 2021 |
Written by: Kirollos Hanna, PharmD, BCPS, BCOP, University of Minnesota Medical Center & Mayo Clinic Download Here Description: Ixazomib is an oral proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy. This PQI highlights the management, safety, and efficacy of ixazomib. Background: Multiple […]
read more
Cemiplimab-rwlc (Libtayo®) Patient Management
September 14, 2021 |
Written By: Marko Skelin MPharm PhD, Assistant Professor, Faculty of Medicine, University of Rijeka Luis Raez, MD, FACP, Memorial Cancer Institute/Memorial Health Care System DOWNLOAD HERE Description: The purpose of this PQI is to discuss the option of using cemiplimab-rwlc for patients with: Locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) previously treated with […]
read more
OPDIVO® is now available in a 120-mg/120mL vial.
September 14, 2021 |
Bristol Myers Squibb has developed a 120-mg/12-mL vial. This vial is available in addition to the current vial sizes (40 mg, 100 mg, and 240 mg). For NDC codes and OPDIVO storage information, see the vial flashcard HERE. Please ensure the 120-mg vial is included in your EHR for prescribing. If you need help adding […]
read more
Loncastuximab tesirine-lply (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma
September 13, 2021 |
Written by: Kelly Valla, PharmD, BCOP, Emory Healthcare Winship Cancer Institute DOWNLOAD HERE Description: The purpose of this PQI is to discuss the clinical considerations around the use of loncastuximab tesirine-lply (Zynlonta®) to optimize the outcomes for patients with relapsed/refractory large B-cell lymphoma. Background: Loncastuximab tesirine-lply is a CD19 directed antibody-drug conjugate with a pyrrolobenzodiazepine […]
read more
Brentuximab Vedotin (Adcetris®): Neuropathy and Neutropenia Management
September 13, 2021 |
Written by: Kirollos Hanna, PharmD, BCPS, BCOP, Mayo Clinic College of Medicine and M Health Fairview and Kayla Randle, PharmD, BCOP, Kaiser Permanente – Southwood Oncology Clinic Download Here Description: Brentuximab vedotin is a CD30-directed antibody drug conjugate (ADC) indicated as front-line treatment for patients with classical stage III/IV Hodgkin’s Lymphoma (cHL) or CD30-expressing peripheral […]
read more
Olaparib (Lynparza®) Clinical Management
September 13, 2021 |
Written by: Katie Carter, PharmD, BCPS, Indiana University Health Download Here Description: Olaparib is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is FDA approved as a targeted therapy for BRCA-mutated breast cancer, ovarian, pancreatic cancer, as well as prostate cancer. This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding […]
read more
Liposomal Daunorubicin-Cytarabine (Vyxeos®) Management
September 13, 2021 |
Written by: Anna Howard, PharmD, BCOP, Billings Clinic Download Here Description: The purpose of this PQI is to discuss the option of using liposomal daunorubicin-cytarabine for patients with newly diagnosed therapy-related Acute Myeloid Leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC).1 Background: Liposomal daunorubicin-cytarabine is a combination of daunorubicin and cytarabine in a fixed molar […]
read more
Ibrutinib (Imbruvica®) Management
September 13, 2021 |
Written by: Jody Agena, PharmD, MBA, BCOPDownload Here Description: Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), a key component of the B-cell receptor and cytokine receptor signaling pathway. BTK inhibition is vital for decreased malignant B-cell proliferation and survival. This molecule disrupts the proliferation of […]
read more
Oncolytic Induced Diarrhea
September 10, 2021 |
Written by: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI will discuss management strategies for oncolytic medication induced diarrhea including combinations of fluid hydration therapies, antimotility agents such as loperamide, and dose modifications. Background: A common side effect with many oncolytic therapies is medication induced diarrhea which can result from chemotherapy or targeted therapy […]
read more
Chemotherapy, Oncolytic, Antiemetic Induced Constipation
September 10, 2021 |
Written by: Brady Quinn, PharmD and Britny Rogala, PharmD, BCOP – University of Rhode Island College of Pharmacy Download Here Description of PQI: Discuss prevention and management strategies for treatment related constipation. Background: The utilization of proper diet, over-the-counter medications, and alternative prescriptions can be helpful for patients suffering from multisource drug induced constipation. […]
read more
Opioid Induced Constipation
September 10, 2021 |
Written by: Neal Dave, PharmD and Julianne Orr, PharmD Download Here Description of PQI: Discuss the prevention and management of opioid induced constipation. Background: Constipation is a major side effect of opioid administration and should be assessed and managed by the healthcare team. In cancer patients receiving chronic opioid therapy, the prevalence of constipation can […]
read more
Non-hormonal Birth Control Alternative with Lactic acid/Citric acid/Potassium Bitartrate (Phexxi®)
September 10, 2021 |
Written By: Natasha Olson, PharmD, NCODA Download Here Description: The purpose of this PQI is to provide proper identification and management of patients who may benefit from the use of non-hormonal contraception using lactic acid/citric acid/potassium bitartrate (Phexxi), a novel non-hormonal, vaginal pH modulator. Background: Lactic acid/citric acid/potassium bitartrate is indicated for the prevention of […]
read more
Proactive Symptom Management in Myelofibrosis
September 10, 2021 |
Written by: Kristyn DiSogra, PharmD, BCOP and Justin Arnall, PharmD, BCOP, Atrium Health Download Here Description: The purpose of this PQI is to highlight implementation of telehealth symptom and risk survey completion by pharmacists or other healthcare providers for myelofibrosis (MF) patients. The goal is to improve provider clinical care pathway adherence and treatment optimization […]
read more
Drug Induced Hand‐Foot Syndrome
September 9, 2021 |
Written by: Jonas Congelli, RPh Hematology Oncology Associates of CNY Download Here Description: To discuss prevention and management of Hand-Foot Syndrome. Background: Palmar-plantar erythrodysesthesia, also known as hand-foot syndrome (HFS) is a widely recognized dose-limiting toxicity of certain chemotherapy agents. A comprehensive list can be found in the supplemental information section. Typically, HFS occurs within the […]
read more
Granisetron (Sancuso®) Transdermal System for Chemotherapy Induced Nausea and Vomiting
September 9, 2021 |
Written by: Latha Radhakrishnan, PharmD, BCPS, BCOPDownload Here Description: The granisetron transdermal system is a 5-HT3 Receptor Antagonist (5-HT3 RA) that allows for an alternate medication delivery compared to oral or parenteral administration. The purpose of this PQI is to review appropriate patient identification and discuss clinical considerations for the use of granisetron in chemotherapy […]
read more
Darolutamide (Nubeqa®) in the Treatment of Non-Metastatic Castration Resistant Prostate Cancer
September 8, 2021 |
Written by: Michelle Phillips, PharmD, BCOP, Wilmot Cancer Center Download Here Description: The purpose of this PQI is a summary of process for initiating and monitoring darolutamide therapy in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Background: Darolutamide is a next-generation androgen receptor antagonist approved in 2019 for the treatment of […]
read more
Telotristat Ethyl (Xermelo®) for the Management of Carcinoid Syndrome Diarrhea
September 7, 2021 |
Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology Download Here Description: This PQI will review appropriate patient identification and management techniques to ensure optimal benefit from telotristat ethyl therapy. Background: A first in class oral tryptophan hydroxylase inhibitor, telotristat ethyl, is approved for use in combination with somatostatin analogues (SSA) therapy in […]
read more
Stomatitis Prophylaxis During Everolimus (Afinitor®) Therapy
September 7, 2021 |
Written by: Matthew Schulz, RPh Rocky Mountain Cancer Centers Download Here Description of PQI: The purpose of this PQI is to identify patients initiating everolimus therapy and could benefit from stomatitis prophylaxis with a steroid mouthwash. Background: Stomatitis is a significant complication associated with mTOR inhibition. In BOLERO-2 patients receiving everolimus/exemestane (EVE/EXE), all grade stomatitis […]
read more
Use of Rucaparib (Rubraca®) In the Treatment of Ovarian, Fallopian Tube, Primary Peritoneal or Prostate Cancer
September 7, 2021 |
Written By: Jon Suyko Pharm.D., BCPS, UC Health Highlands Ranch DOWNLOAD HERE Description: The purpose of this PQI is to discuss the various indications for rucaparib (Rubraca). Background: Rucaparib is an oral tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) PARP 1, PARP 2 and PARP 3, with antineoplastic activity.1 PARPs are a group of […]
read more
Enzalutamide (Xtandi®) for patients with castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer
September 7, 2021 |
Written By: Samantha Larson, PharmD, M Health Fairview Download Here Positive Quality Intervention: Enzalutamide (Xtandi) In Castration-Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer Description: The purpose of this PQI is a summary of process for initiating and monitoring enzalutamide therapy in patients with either castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer (mCSPC).1 Background: […]
read more
Trilaciclib (Cosela™) Management
September 7, 2021 |
Written By: Autumn Alvarez, PharmD, BCPS, Blue Ridge Cancer Care Download Here Description: The purpose of this PQI is to describe the indication, pharmacology and dosing of trilaciclib. Background: Trilaciclib is a CDK 4/6 inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients undergoing chemotherapy with a platinum/etoposide or topotecan containing regimen for […]
read more
Lurbinectedin (ZepzelcaTM) for Small Cell Lung Cancer
September 3, 2021 |
Written By: Luis E. Raez, MD, FACP Memorial Healthcare System DOWNLOAD HERE Description: The purpose of this PQI is to evaluate the use of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. Background: Small cell lung cancer (SCLC), which accounts for around […]
read more
NCODA Expands Patient and Caregiver Resource to Improve Understanding and Outcomes
September 1, 2021 |
FOR IMMEDIATE RELEASE SEPTEMBER 1, 2021 Media Contact: Katie Edmiston | Marketing Manager Katie.Edmiston@NCODA.org NCODA Expands Patient and Caregiver Resource to Improve Understanding and Outcomes CAZENOVIA, NY – September 1, 2021 – With the success of the highly utilized NCODA conceived OCE (Oral Chemotherapy Education) online resource, the collaboration with the Oncology Nursing Society […]
read more
Netupitant/Fosnetupitant and Palonosetron (Akynzeo®) for Chemotherapy-Induced Nausea and Vomiting
August 11, 2021 |
Written By: Doug Braun, PharmD and Emily Gallagher, PharmD | AON Download Here This PQI serves to review the use of the combination product Akynzeo® for patients with acute and delayed chemotherapy-induced nausea and vomiting (CINV). Background1-5: Nausea and vomiting from chemotherapy can occur acutely (within 24 hours) or have a more delayed onset (>24 […]
read more
NCODA Structures Medically Integrated Pharmacy Accreditation
August 10, 2021 |
FOR IMMEDIATE RELEASE AUGUST 10, 2021 NCODA Structures Medically Integrated Pharmacy Accreditation Cazenovia, New York – As the leading not-for-profit association for the patient-centered medically-integrated oncology community, NCODA, Inc. is excited to announce the new NCODA Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) Accreditation Program. The program, based on compliance with the […]
read more
BIDEN ADMINISTRATION PROPOSES WITHDRAW FROM MOST FAVORED NATION
August 9, 2021 |
FOR IMMEDIATE RELEASE August 9th 2021 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org BIDEN ADMINISTRATION PROPOSES WITHDRAW FROM MOST FAVORED NATION NCODA has been in opposition of the Most Favored Nation (MFN) model for Medicare patients since it […]
read more
Florida Cancer Specialists & Research Institute to mandate COVID-19 vaccines for its workforce
August 9, 2021 |
Florida Cancer Specialists & Research Institute to mandate COVID-19 vaccines for its workforce Increasing vaccination rates essential to protecting patients and staff Fort Myers, Fla., Aug. 3, 2021 — In response to growing concerns amidst the statewide surge of COVID-19 variants, Florida Cancer Specialists & Research Institute (FCS) will require all physicians and team members obtain their first […]
read more
Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
August 5, 2021 |
Written By: Jeff Engle, PharmD, MS, M Health Fairview University of Minnesota Medical Center Download Here The purpose of this PQI is to discuss the clinical considerations around the use of tafasitamab-cxix (Monjuvi®) to optimize the outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Background: DLBCL is an aggressive lymphoma and is the […]
read more
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
August 2, 2021 |
FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer Dose escalation of NERLYNX therapy demonstrated improved management and prevention of Grade 3 diarrhea LOS ANGELES, Calif., July 1, 2021 – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug […]
read more
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
July 27, 2021 |
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients EZH2Now Testing Program is first of its kind to offer national single gene testing for EZH2 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the EZH2Now Testing Program, an Epizyme […]
read more
CoPay Accumulator Patient Resources
July 15, 2021 |
CoPay Accumulator Patient Resources Educate your patients with resources like this CoPay Accumulator video along with our printable brochures that will provide valuable information to your patients as they manage the financial impact of copay accumulator programs. NCODA’s Legislative & Policy Advisory Committee continues to push for increased awareness to help patience afford their medications […]
read more
LOUISIANA SIGNS LAW TO PROHIBIT WHITE BAGGING
June 29, 2021 |
FOR IMMEDIATE RELEASE June 29th 2021 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org LOUISIANA SIGNS LAW TO PROHIBIT WHITE BAGGING June has been filled with announcements and progress in the world of oncology at state legislatures throughout the […]
read more
KITE ANNOUNCES YESCARTA® CAR T-CELL THERAPY IMPROVED EVENT-FREE SURVIVAL BY 60% OVER CHEMOTHERAPY PLUS STEM CELL TRANSPLANT IN SECONDLINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
June 28, 2021 |
CONTACTS: Jacquie Ross, Investors (650) 358-1054 Mary Lynn Carver, Media (410) 443-1853 For Immediate Release KITE ANNOUNCES YESCARTA® CAR T-CELL THERAPY IMPROVED EVENT-FREE SURVIVAL BY 60% OVER CHEMOTHERAPY PLUS STEM CELL TRANSPLANT IN SECONDLINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA — Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial […]
read more
Bayer Introduces Updated Packaging for Stivarga® (regorafenib) to Help Accommodate Dispensing
June 24, 2021 |
WHIPPANY, N.J., June 23, 2021 – Bayer announced the availability of new packaging for the company’s treatment Stivarga® (regorafenib) to support dispensing. Stivarga is now available in four 21-count bottles, replacing the previous packaging of three 28-count bottles. “The new packaging contains four 21-count bottles to help further accommodate dispensing of Stivarga,” said Ray Bailey, RPh, […]
read more
NORTH CAROLINA PUSHING TO ENHANCE CONTINUITY OF CARE
June 18, 2021 |
FOR IMMEDIATE RELEASE June 18th 2021 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org NORTH CAROLINA PUSHING TO ENHANCE CONTINUITY OF CARE Earlier this week the North Carolina Senate unanimously approved a bill to regulate Pharmacy Benefit Managers and provide […]
read more
FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
June 17, 2021 |
June 16, 2021 at 3:50 PM EDT — First precision therapy that specifically targets the primary driver of the disease —— Durable clinical responses, including complete remissions, shown in patients with or without prior treatment —— Full approval supported by robust efficacy and safety data from two clinical trials —— Blueprint Medicines to host investor […]
read more
NEW YORK STATE PUSHES ONCOLOGY MOMENTUM FORWARD
June 11, 2021 |
FOR IMMEDIATE RELEASE 6/11/21 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org NEW YORK STATE PUSHES ONCOLOGY MOMENTUM FORWARD The legislative victories continue to pile up, recently we have seen major victories in Texas, Tennessee and now in […]
read more
Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets
June 10, 2021 |
NEWTON, Mass., June 3, 2021 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that three new strength tablets for XPOVIO, the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, are now commercially available. The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) […]
read more
TENNESSEE REGULATES PBM; WIN FOR ONCOLOGY PATIENTS
June 8, 2021 |
FOR IMMEDIATE RELEASE 6/8/21 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org TENNESSEE REGULATES PBM; WIN FOR ONCOLOGY PATIENTS NCODA was thrilled to announce the major legislative victory in the state of Texas that regulates Pharmacy Benefit Managers (PBMs). […]
read more
GOV. ABBOTT (TX) SIGNS PBM LEGISLATION – A VICTORY FOR ONCOLOGY PATIENTS
May 27, 2021 |
FOR IMMEDIATE RELEASE 5/27/21 STATEMENT FROM NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org GOV. ABBOTT (TX) SIGNS PBM LEGISLATION – A VICTORY FOR ONCOLOGY PATIENTS The world of oncology has numerous advocates for patients and their well-being, NCODA is […]
read more
RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 24, 2021 |
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, […]
read more
NCODA Welcomes New Executive Council Member
May 20, 2021 |
FOR IMMEDIATE RELEASE May 20, 2021 NCODA Welcomes New Executive Council Member Cazenovia, NY – NCODA, Inc. is pleased to announce the addition of a new Executive Council member. Dallas Lawry, DNP, FNP-C, OCN, Clinical Oncology Nurse III at UCLA Medical Center in Santa Monica Hospital, California was appointed to the Council in May […]
read more
LEGISLATIVE VICTORIES FOR ONCOLOGY PATIENTS IN ALABAMA & OKLAHOMA
May 17, 2021 |
FOR IMMEDIATE RELEASE 5/14/21 STATEMENT FROM NCODA’s Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org LEGISLATIVE VICTORIES FOR ONCOLOGY PATIENTS IN ALABAMA & OKLAHOMA The NCODA Legislative & Policy Advisory Committee wants to commend the Oklahoma Legislature and Governor Kevin Stitt for signing […]
read more
TAKING A STAND FOR TEXANS WITH CANCER
May 12, 2021 |
May 12, 2021 Texas Oncology’s leaders and physicians serve patients and their families in many ways – including those that lead them to the floor of the Texas State Capitol in Austin. Recently, Steven R. Paulson, M.D., president and chairman of the board, Texas Oncology; Kathryn Hudson, M.D., hematologist and medical oncologist at Texas Oncology–Austin […]
read more
Patient Access Network (PAN) Foundation | Patient Assistance Funds
May 6, 2021 |
The PAN Foundation is a national organization dedicated to helping federally and commercially insured people living with life-threatening, chronic, and rare diseases with the out-of-pocket costs for their prescribed medications. Learn more about certain patient assistance funds below. Chronic Lymphocytic Leukemia The PAN Foundation’s chronic lymphocytic leukemia (CLL) patient assistance fund provides a 12- month grant […]
read more
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
April 29, 2021 |
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer April 27, 2021 – Prescription Drug User Fee Act (PDUFA) Target Action Date Set for October 26, 2021 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that that the U.S. […]
read more
FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker
April 26, 2021 |
For Immediate Release: April 22, 2021 Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that […]
read more
NCODA Welcomes New Executive Council Member – Lucius Daniel, PharmD
April 26, 2021 |
FOR IMMEDIATE RELEASE April 26, 2021 NCODA Welcomes New Executive Council Member Cazenovia, NY – NCODA, Inc. is pleased to announce our expanded leadership to the Executive Council. Lucius Daniel, PharmD, the Lead Clinical Pharmacy Specialist with Karmanos Specialty Pharmacy in Troy, Michigan, has joined the Executive Council as of April 2021. Lucius has […]
read more
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
April 12, 2021 |
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies While the median progression free survival (PFS) for Sarclisa combination therapy […]
read more
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
March 23, 2021 |
– FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies – – AVEO ACE Patient Support Program in Place to Assist with Access, Affordability, and Treatment Adherence – March 22, 2021 07:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO) today announced […]
read more
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
March 8, 2021 |
SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The approval makes Yescarta the first chimeric […]
read more
Now Approved: PEPAXTO® (melphalan flufenamide); Oncopeptides, Inc.
March 5, 2021 |
March 1, 2021 —U.S. Commercial Launch Underway— WALTHAM — March 1, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in […]
read more
ANY WILLING PROVIDER (AWP) – STILL A MAJOR ISSUE IN ONCOLOGY
February 23, 2021 |
FOR IMMEDIATE RELEASE February 23, 2021 STATEMENT FROM – NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org ANY WILLING PROVIDER – STILL A MAJOR ISSUE IN ONCOLOGY As we begin to navigate 2021, it is important for the oncology community to speak […]
read more
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
February 23, 2021 |
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50% Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics frequently underrepresented in advanced NSCLC trials This is the third approval for Libtayo in the U.S. […]
read more
Larotrectinib (Vitrakvi®) Overview
February 12, 2021 |
Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to help provide awareness of larotrectinib and educate on management techniques. Background: Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that: Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired […]
read more
NCODA Welcomes Collaboration with Evofem Biosciences to Educate Oncology Community about Phexxi® – A Non-Hormonal Birth Control Option for Women with Cancer
February 10, 2021 |
Cazenovia, NY – NCODA, Inc. is pleased to announce its collaboration with Evofem Biosciences to positively impact the quality of life for female patients undergoing treatment, those recovering from cancer, and survivors by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate). […]
read more
NCODA Welcomes Five New Executive Council Members
February 8, 2021 |
FOR IMMEDIATE RELEASE February 8, 2021 NCODA Welcomes Five New Executive Council Members Cazenovia, NY – NCODA, Inc. is pleased to announce the addition of five new members to the Executive Council. Paul Chadwick (Florida Cancer Specialists & Research Institute), Lucio Gordan, MD (Florida Cancer Specialists & Research Institute), Benjamin Lowentritt, MD (Chesapeake Urology), Stacey […]
read more
Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer
February 4, 2021 |
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), a premier educational platform for community and academic oncology practices nationwide, are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and […]
read more
Exelixis announces FDA approval for CABOMETYX(R) (cabozantinib) with OPDIVO(R) (nivolumab)
January 27, 2021 |
Exelixis is pleased to announce the FDA approval of its first combination therapy–CABOMETYX + OPDIVO–for the first-line treatment of patients with advanced renal cell carcinoma (aRCC).1 This new approval in aRCC is supported by clinical data from the CheckMate-9ER trial. The major efficacy outcome measure was PFS.* Additional efficacy outcome measures were OS and ORR.* […]
read more
New Indication for ENHERTU® (fam-trastuzumab deruxtecan-nxki)
January 20, 2021 |
Daiichi Sankyo and AstraZeneca are excited to announce that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for a new indication. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate that was recently approved for use in adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based […]
read more
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 19, 2021 |
Accelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of […]
read more
Most Favored Nation: Temporary Restraining Order Issued
December 23, 2020 |
FOR IMMEDIATE RELEASE December 23, 2020 STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org MOST FAVORED NATION: TEMPORARY RESTRAINING ORDER ISSUED NCODA has been in opposition of the Most Favored Nation (MFN) model for Medicare patients since it was announced late […]
read more
MOST FAVORED NATION MODEL: NOT THE ANSWER FOR PATIENTS
December 21, 2020 |
FOR IMMEDIATE RELEASE December 18, 2020 STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone, NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org https://www.ncoda.org MOST FAVORED NATION MODEL: NOT THE ANSWER FOR PATIENTS NCODA is in opposition of the Most Favored Nation (MFN) model for Medicare patients that would negatively affect patient access […]
read more
Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma
December 18, 2020 |
Written by: Houston Holmes, MD, Texas Oncology Download Here Positive Quality Intervention: Tazemetostat (Tazverik®) management in Relapsed/Refractory Follicular Lymphoma Description: This PQI will discuss the initiation and management of tazemetostat in the treatment of relapsed or refractory (r/r) follicular lymphoma (FL) Background: Tazemetostat is a methyltransferase inhibitor indicated for the treatment of adults and pediatric […]
read more
SUPREME COURT RULES UNANIMOUS: REGULATES PHARMACY BENEFIT MANAGERS
December 11, 2020 |
FOR IMMEDIATE RELEASE December 11, 2020 STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone, NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org https://www.ncoda.org SUPREME COURT RULES UNANIMOUS: REGULATES PHARMACY BENEFIT MANAGERS Decision confirms that states will have the right to regulate; brings clarity and optimism Yesterday, December 10, 2020, the United States […]
read more
Intermountain Healthcare
November 19, 2020 |
MISSION STATEMENT/PHILOSOPHY: Our Mission Helping people live the healthiest lives possible® Our Vision Be a model health system by providing extraordinary care and superior service at an affordable cost. LOCATION(S): MEDICAL ONCOLOGY Offices 3131 La Canada Street, Ste 140 Las Vegas, NV 89169 (702) 735-7154 (702) 735-7153 Fax 2650 Tenaya Way, Ste 201 Las […]
read more
Use of Rasburicase (Elitek®) for Treatment of Tumor Lysis Syndrome
November 19, 2020 |
Written by: Marie C. Rush, PharmD, CPP, BCOP, Wake Forest Baptist Health Download Here Description: The purpose of this PQI is to identify appropriate dosing of rasburicase based upon uric acid levels. Background: Rasburicase is an FDA approved intravenous medication for the management of serum uric acid levels in the setting of anticancer therapy that is expected to result in tumor lysis.1,2 While rasburicase breaks down uric acid […]
read more
UnitedHealthcare (UHC) Announcement
November 16, 2020 |
FOR IMMEDIATE RELEASE Cazenovia, NY – On November 12th, after feedback from healthcare professionals, UnitedHealthcare (UHC) announced that the implementation of their Accumulator Adjustment – Medical Benefit Program for their commercial members will NOT take effect on Jan. 1, 2021. This program would have prevented manufacturer assistance and co-pay programs from being accounted towards patient […]
read more
National Broadcast: New Evidence in First-Line AML and Exploring Outcomes with Fixed-Duration Treatment in CLL
October 28, 2020 |
Join AbbVie for their upcoming National Broadcast: New Evidence in First-Line AML and Exploring Outcomes with Fixed-Duration Treatment in CLL, taking place on Thursday, 11/12 and Tuesday, 11/17 across multiple time zones. These educational events are in support of oncologists and care teams. You may tailor the program to your audience by selecting to have the […]
read more
Oklahoma Cancer Specialists and Research Institute
October 9, 2020 |
MISSION STATEMENT/PHILOPSOPHY: To provide the most powerful team of cancer experts investing in the health of our patients by pursuing the most advanced and innovative treatment methods and providing unrelenting dedication to our patients. LOCATIONS: Tulsa Oklahoma Bartlesville Oklahoma McAlester Oklahoma PRACTICE DETAILS (how many providers, how many employees, etc): 10 Medical Oncologists 4 Gyn […]
read more
Oncolytics Today Completes BPA Worldwide Initial Business Publication Audit
October 5, 2020 |
ONCOLYTICS TODAY Completes BPA Worldwide Initial Business Publication Audit SHELTON, CT, 10/5/20 – Oncolytics Today has completed its BPA Worldwide business publication audit. Glenn J. Hansen, BPA Worldwide President, praised Oncolytics Today for voluntarily opening its records to independent verification and documentation of its circulation data. Hansen pointed out that the audit facilitates the buying […]
read more
Beacon Cancer Care
September 11, 2020 |
MISSION STATEMENT/PHILOPSOPHY: To meet patients wherever they are on their cancer journey and walk with them on that journey; to provide compassionate, personalized cancer care for an unparalleled patient experience. LOCATIONS: Coeur D’ Alene, ID PRACTICE DETAILS (how many providers, how many employees, etc): 3 MO/DO 2 ARNP 20-25 employees INTRODUCTION TO PHARMACY SERVICES STAFF […]
read more
Nubeqa Update – New Safety Data Poster Presented at ASCO
September 10, 2020 |
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for […]
read more
Approval of GAVRETO™ (pralsetinib)
September 8, 2020 |
CAMBRIDGE, Mass., September 4, 2020 – Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung […]
read more
Cone Health Cancer Center at Wesley Long
August 31, 2020 |
MISSION STATEMENT/PHILOPSOPHY: Our vision is to provide an exceptional, unsurpassed health care experience at the Cone Health Cancer care program. Our mission is to create a patient-centered, safe, high-quality, comprehensive program to meet the needs of our community. Through an empowered team, we will provide outstanding, collaborative, coordinated care with empathy and compassion that will […]
read more
PTCE and NCODA to Partner in Bringing Oncology-Focused Continuing Education to the NCODA Membership
August 26, 2020 |
The industry-leading continuing pharmacy education provider becomes sole provider for association’s three major meetings through 2021 (CRANBURY, N.J. – August 23, 2020) – PTCE proudly announces it is now the exclusive continuing education (CE) provider for the National Community Oncology Dispensing Association, Inc. (NCODA) 2020-2021 meetings. See Full Press Release here
read more
FDA granted accelerated approval to tazemetostat for follicular lymphoma
July 7, 2020 |
On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, […]
read more
FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma
June 29, 2020 |
On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Learn more Product Information Prescribing Information Relapsed or refractory […]
read more
Oncolytics Today Applies For BPA Worldwide Business Publication Membership
June 23, 2020 |
Shelton, CT June 2020 – Oncolytics Today announced it has applied for business publication membership in BPA Worldwide. Oncolytics Today is published by the National Community Oncology Dispensing Association, Inc. (NCODA) (Cazenovia, NY). BPA Worldwide will analyze Oncolytics Today’s circulation size – including print and digital editions – source make-up, demographics and geographic coverage. The […]
read more
UNM Comprehensive Cancer Center
June 5, 2020 |
MISSION STATEMENT/PHILOPSOPHY: To ensure that all New Mexicans have access to world-class cancer care and benefit from advances in cancer research, the UNM Comprehensive Cancer Center will provide outstanding cancer diagnosis and treatment, conduct world-class research to discover the causes and the cures for cancer, educate the next generation of cancer healthcare professionals, and overcome […]
read more
St. Elizabeth Healthcare
May 13, 2020 |
MISSION STATEMENT/PHILOPSOPHY: St. Elizabeth is here for each patient along every step of their journey. We offer a unique approach to patient care that helps us to ensure that all patient needs are met and can be found in one location. LOCATION(S): St. Elizabeth Healthcare is located in Northern Kentucky with locations in Edgewood, Florence, […]
read more
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
May 4, 2020 |
HORSHAM, Pa., May 1, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. DARZALEX FASPRO™ is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as […]
read more
Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
April 21, 2020 |
Seattle Genetics, Inc. is pleased to inform you that on April 17, 2020, the FDA approved TUKYSA tablets for oral administration. TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or […]
read more
Bristol Myers Squibb (BMS) Expanded Patient Support Program Overview
April 14, 2020 |
In light of the developing situation around COVID-19, we would like to share immediate action Bristol Myers Squibb is taking to support the health and well-being of patients, customers and employees during this time. Bristol Myers Squibb is expanding its longstanding patient support programs to help eligible unemployed patients in the U.S. who have lost […]
read more
Clearview Cancer Institute
April 10, 2020 |
MISSION STATEMENT/PHILOPSOPHY: Clearview Cancer Institute is committed to providing cutting edge quality, compassionate, comprehensive care. LOCATION(S): Anniston Location, Athens Location, Cullman Location, Decatur Location, Florence Location, Huntsville-Crestwood Location, Huntsville- Main Location, Jasper Location, Scottsboro Location PRACTICE DETAILS (how many providers, how many employees, etc): Clearview Cancer Institute Consists of 22 Physicians and 20 APP’s QUALIFICATIONS/CREDENTIALS […]
read more
Oncology Consultants
March 24, 2020 |
MISSION STATEMENT/PHILOPSOPHY: Oncology Consultants mission is a commitment to provide state-of-the-art cancer treatment in a caring environment. LOCATION(S): OC Pharmacy located in the Memorial City Area OC Pharmacy II located in the Medical Center OCRX Pharmacy Solutions located in the Katy Area PRACTICE DETAILS (how many providers, how many employees, etc): Oncology Consultants was formed […]
read more
**IMPORTANT UPDATE** NCODA SPRING FORUM 2020
March 9, 2020 |
NCODA Spring Forum 2020 Transitions to Virtual E-Meeting March 10, 2020 3pm Eastern To our valued members and corporate partners, In alignment with our Guiding Values, 1) Patient-Centered and 2) Always Collaborative, NCODA is taking all necessary precautions in order to provide our members and corporate partners a value-added experience, while remaining vigilant concerning the […]
read more
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
March 3, 2020 |
BRIDGEWATER, N.J., March 2, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa is expected to be available to patients […]
read more
Shenandoah Oncology
February 14, 2020 |
MISSION STATEMENT/PHILOSOPHY: Shenandoah Oncology exists to provide comprehensive, compassionate care to our patients. It is our goal to offer the most current, state-of-the art oncology and hematology care. We will offer clinical trials, oral and IV indigent drug programs, and other ancillary services. LOCATION(S): Shenandoah Oncology has one office located in Winchester, Virginia. We serve […]
read more
NCODA Announces the defining of the Medically Integrated Dispensing Pharmacy
January 27, 2020 |
FOR IMMEDIATE RELEASE January 27, 2020 NCODA Announces the defining of the Medically Integrated Dispensing Pharmacy Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA) is pleased to announce we have conclusively defined the Medically Integrated Dispensing Pharmacy. This definition serves to empower the NCODA membership to fulfill their cancer care […]
read more
Gettysburg Cancer Center
January 9, 2020 |
MISSION STATEMENT/PHILOPSOPHY: Our mission is to provide individualized treatment, utilizing the best technical approach, and recognizing each patient’s psychological, emotional, and spiritual needs during their journey with their illness and healing. For more than 25 years, Gettysburg Cancer Center has been committed to providing cancer care in a community-based setting close to home. Our all-encompassing […]
read more
Houston Methodist Hospital Texas Medical Center
December 13, 2019 |
MISSION STATEMENT/PHILOPSOPHY: To provide high quality, cost-effective health care that delivers the best value to the people we serve in a spiritual environment of caring in association with internationally recognized teaching and research. LOCATION(S): Houston Methodist Hospital Texas Medical Center PRACTICE DETAILS: 12 Physicians: Medical oncology, breast oncologist and hematologists. 5 medical oncologist on their […]
read more
CALQUENCE® (acalabrutinib) Receives US FDA Approval for New Indication
November 25, 2019 |
The US Food and Drug Administration (FDA) has approved CALQUENCE® (acalabrutinib) capsules for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).[i] CALQUENCE for CLL was granted Breakthrough Therapy Designation by the FDA, and the approval was granted under the FDA’s Real Time Oncology Review (RTOR) and newly established Project Orbis […]
read more
University of Illinois Cancer Center
November 19, 2019 |
MISSION STATEMENT/PHILOPSOPHY: In collaboration with our academic partners, our mission is to advance healthcare to improve the health of our patients and communities, promote health equity and develop the next generations of healthcare leaders. LOCATION(S): Chicago’s west side PRACTICE DETAILS: 465 bed Hospital, 7 Health Science Colleges Heme/Onc 19 chair outpatient infusion center, 13 attendings, […]
read more
Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
October 23, 2019 |
Bristol-Myers Squibb’s study met its co-primary endpoint of overall survival with Opdivo® (nivolumab) plus low dose Yervoy® (ipilimumab) vs. chemotherapy in first-line Non-Small Cell Lung Cancer patients whose tumors expressed PD-L1 ≥1%. This is the third tumor type in which Opdivo plus Yervoy demonstrates overall survival benefit in a Phase 3 Trial. Learn more HERE
read more
Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
October 21, 2019 |
AstraZeneca’s trastuzumab deruxtecan was granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer.Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today. Learn more at: https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019.html
read more
FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
October 3, 2019 |
LOS ANGELES, Calif., Oct. 2, 2019 – Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement for NERLYNX® (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer. With the approval of the labeling supplement, the label now includes safety information based on […]
read more
University of Minnesota discovery is now a first-in-human clinical trial for leukemia
September 24, 2019 |
MINNEAPOLIS, MN- September 19, 2019 -The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia. The study is opening exclusively at the University of Minnesota Medical […]
read more
Miami Cancer Institute
September 17, 2019 |
MISSION STATEMENT/PHILOPSOPHY: Mission: Miami Cancer Institute provides comprehensive care, to patients with cancer and their families, in a multi-disciplinary setting, with the most innovative, evidence-based approaches available. We focus on compassionate care, delivered in a timely manner, with ready access to highly skilled and professional teams of caregivers. Vision: Miami Cancer Institute strives to be […]
read more
Celgene announces Phase 3 successes for CC-486 for use as maintenance therapy in Acute Myeloid Leukemia.
September 13, 2019 |
Top-line analysis showed a highly statistically significant and clinically meaningful improvement in overall survival for CC-486 Celgene plans regulatory submissions beginning in 1H 2020 SUMMIT, N.J.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational […]
read more
Medically integrated pharmacies make patient care more efficient
September 9, 2019 |
Loren Bonner, senior editor As more patients with cancer are treated with oral chemotherapy drugs, a new way of dispensing is slowly becoming more popular. Medically integrated dispensing, or medically integrated pharmacies, may not be known to many yet. However, if the desire is to receive more personal and coordinated care, patients with cancer should become […]
read more
U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
August 29, 2019 |
The FDA recently approved Inrebic® (Fedretinib) for Myelofibrosis, the first new treatment in decades. Available as a once-daily oral dose, this is a new option for patients. Learn more: https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx
read more
Local pharmacist inspires patient-choice state law
August 27, 2019 |
JOHNS CREEK, Ga. The Pharmacy Anti-Steering and Transparency Act, which will go into effect Jan. 1, 2020, prohibits insurers and benefits managers who have ownership in a pharmacy from steering patients to that business. The law endeavors to reduce conflicts of interests, increase transparency and give patients more choice. The law was inspired in part […]
read more
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer
August 27, 2019 |
A recently published Phase III Trial by Athenex, Inc. showed that oral paclitaxel in combination with encequidar was superior to IV paclitaxel for Overall Response Rate in Metastatic Breast Cancer. Patients in the oral combination group also had less incidence of neuropathy than the intravenous group. Learn more at: https://ir.athenex.com/news-releases/news-release-details/athenex-announces-oral-paclitaxel-and-encequidar-had
read more
Arizona Blood & Cancer Specialists
August 15, 2019 |
MISSION STATEMENT / PHILOSOPHY: With experience, commitment and a shared vision of how we can positively impact patients’ lives, we’re changing the future of healthcare in our community. Understanding that each of our patients is a unique individual, our goal is to: provide the most advanced, clinically-proven treatments for their disease; provide access to clinical […]
read more
Oregon passes PBM legislation
August 7, 2019 |
On July 17th, the governor of Oregon signed a bill into the law; Oregon House Bill 2185 has been passed unanimously, imposing new requirements on Pharmacy Benefit Managers (PBMs) registered in Oregon. Effective January 1st, 2020, PBMs may not require a prescription to be filled or refilled by a mail order pharmacy if a dispensing […]
read more
White House drops Drug Rebate Reform
July 12, 2019 |
Although drug rebates have been an area of high focus for reform, the Trump Administration decided yesterday to withdraw its plan to eliminate rebates from government-sponsored drug plans. Read more
read more
Letter to the Committee on Finance – Phair Pricing Act (S.640)
July 2, 2019 |
Letter to the Committee on Finance – Phair Pricing Act (S.640) The Honorable Chuck Grassley Chairman Committee on Finance 135 Hart Senate Office Building United States Senate Washington, D.C. 20510 The Honorable Ron Wyden Ranking Member Committee on Finance 221 Dirksen Senate Office Building United States Senate Washington, D.C. 20510 Dear Chairman Grassley and […]
read more
CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer
July 2, 2019 |
Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health Download Here Cyclin-dependent kinase (CDK) 4/6 inhibitors have demonstrated significant advances in the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor (HER2) negative advanced breast cancer. While current available data do not support the preferential use of one agent over […]
read more
NCODA Patient Surveys Support the Need for Medically Integrated Pharmacies
June 20, 2019 |
Kirollos S. Hanna, PharmD, BCPS, BCOP Oral oncolytics, or oral chemotherapies, have significantly impacted the treatment of cancer. They enable patients to conveniently manage treatment in their homes. Despite the rapid growth, therapeutic advances, novel mechanisms of actions, and improved outcomes associated with these agents, the dispensing process remains inadequate. As a result of rising drug […]
read more
Statins reduce stroke risk in cancer patients
June 20, 2019 |
A recent study evaluated chest, head and neck cancer patients receiving radiation and determined that use of statin medications can reduce the risk of stroke by 32% (statistically significant). The effects of radiation can cause scarring and thickening of the arteries, which can lead to blockages down the line; statins help protect the arteries and […]
read more
New Jersey Urology
June 18, 2019 |
MISSION STATEMENT/PHILOPSOPHY: Mission: To deliver cutting-edge, compassionate, integrated urologic care, supported by evidence-based medicine, that optimizes quality of life for our patients while increasing value to all stakeholders. Vision: We will serve as the national leader in integrated urologic healthcare by setting the standard for patient experience, employee satisfaction, and provider excellence. LOCATION(S): 43 total (https://www.njurology.com/locations/) […]
read more
SQ Administration of Daratumumab: New Option for Patients
June 17, 2019 |
A recent study found that patients receiving Daratumumab treatment may benefit from an alternative dosing technique of subcutaneous (SQ) administration vs. the traditional IV infusion. Clinicians should be aware of advancing developments that have the potential to reduce the treatment burden and positively impact a patient’s quality of life. READ MORE HERE
read more
Phair Pricing Act and DIR Fees
June 14, 2019 |
Although CMS announced that it would not implement DIR fee reform for 2020, some members of Congress are still attempting to address the issue via the Phair Pricing Act (S. 640). Certain advocacy groups have made the argument that DIR fee reform may lead to lower costs for patients and provide more pricing transparency for pharmacy […]
read more
Congratulations to Norton Healthcare’s 2019 Nurses of the Year
May 17, 2019 |
Mary Anderson, Oral Chemotherapy Nurse Navigator at Norton Cancer Institute and NCODA member was recognized by Norton Healthcare for her exceptional service with their 2019 “Nurse of the Year” award. This award was presented May 13 at a banquet honoring the finest of its more than 5,350 nursing staff members! Read More
read more
CMS issues final Drug Pricing Rule
May 17, 2019 |
Although antineoplastics have retained position as a protected class of medicines with open formularies, CMS did agree to implement Step Therapy with Medicare B medications. And despite receiving over 4000 comments regarding price concessions and DIR fees, the agency has decided to not include a proposal to pass on price concessions negotiated by the pharmacy to […]
read more
Virginia Cancer Institute
May 6, 2019 |
MISSION STATEMENT/PHILOSOPHY: We at Virginia Cancer Institute are dedicated to the delivery of the highest quality medical care to our patients. We are committed to treating our patients with the utmost respect and compassion. We will strive to conduct our practice in a manner in which all employees and outside healthcare providers are treated with […]
read more
Proposal for the Step Therapy Process into Medicare Plans
May 1, 2019 |
On Tuesday, The House of Representatives discussed the Trump proposal for the institution of step-therapy process into medicare plans. Read more
read more
Barry D. Brooks, M.D., Joins NCODA Executive Council
April 26, 2019 |
FOR IMMEDIATE RELEASE April 26, 2019 Barry D. Brooks, M.D., Joins NCODA Executive Council Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA)is pleased to announce the addition of Barry D. Brooks, M.D. to their Executive Council. Dr. Brooks joined the Council in April. Barry D. Brooks, M.D., is a hematologist and […]
read more
CMS to allow copay accumulators: when generics are available
April 21, 2019 |
In what initially appeared to be a move that directly opposed the efforts of state legislation recently passed in the Virginias, CMS is allowing the use of copay accumulators but only in situations in which a generic drug is available. Luckily for our cancer patients, this should largely not affect them (as copay cards are […]
read more
Clinical Awareness Highlight: Ovarian Cancer
April 21, 2019 |
“All eligible patients with ovarian cancer deserve informed counseling regarding the pros and cons of maintenance therapy, and the option of maintenance treatment in these regulatory approved settings.” This article from the Oncologist provides and nice summary and valuable insight into the current state of affairs for ovarian cancer patients. Free-registration link here The Oncologist-2019-Randall-theoncologist.2019-0020
read more
Senate hearing with PBMs misses the mark in oncology
April 10, 2019 |
A US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients. NCODA notes that the Executives from these companies dodged key questions around their policies’ impact on cancer patients. We will continue to support state legislation that increases transparency with the PBMs […]
read more
Alabama Oncology
April 10, 2019 |
MISSION STATEMENT/PHILOSOPHY: Alabama Oncology is a community-based physician practice that provides patients with increased access to integrated, evidence-based cancer care and clinical research throughout central Alabama. We are dedicated to the health and well-being of patients with cancer and blood disorders and strive to provide outstanding care while being respectful and sensitive to the individual […]
read more
NCODA Welcomes Three New Executive Council Members
March 29, 2019 |
FOR IMMEDIATE RELEASE March 29, 2019 Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA)is pleased to announce the addition of three new members to the Executive Council. Randy Erickson, RN, BSN, MBA, James Gilmore, PharmD, and Kirollos Hanna, PharmD, BCPS, BCOP joined the Council in March. Randy Erickson currently serves as Chief […]
read more
Landmark legislation blocks copay accumulators in VA
March 28, 2019 |
Virginia just became the first state in the nation to pass laws to protect patients by blocking copay accumulators. NCODA applauds this effort to lower drug costs for patients and increase access to anti-cancer medications. We will continue to watch and support these efforts as they gain more support across the country. Read more
read more
Compliance/Adherence with oral oncolytics: risk or benefit?
March 26, 2019 |
Sending a patient home with their anti-cancer medication incurs some advantages and disadvantages; data supports the use of medically-integrated teams to overcome the potential downfalls of outpatient therapy including access issues and side effect management. NCODA agrees that the best site of care for a patient is with their oncologist and the multi-disciplinary team. Read […]
read more
Florida Cancer Specialists Published in the Journal of Oncology Pharmacy Practice
March 25, 2019 |
Natasha Khrystolubova is one of the lead author of the Journal of Oncology Pharmacy Practice article, Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. An NCODA practice working to make a difference in the pharmacy to positively impact patient care. Florida […]
read more
NCODA Announces Dr. Mario Lacouture as Director of the Medical Advisory Board for Treatment Support Program
March 19, 2019 |
FOR IMMEDIATE RELEASE March 15, 2019 NCODA Announces Dr. Mario Lacouture as Director of the Medical Advisory Board for Treatment Support Program Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA) Executive Council is pleased to announce that Mario Lacouture, M.D. will be joining the Treatment Support Program as Director of the Medical […]
read more
OptumRX / UHC to “pass rebates to more clients”
March 13, 2019 |
Drug pricing, manufacturer rebates, and PBM transparency are all critical questions that are being asked of today’s insurers; unfortunately, this particular response from UHC might actually push patients away from the medically-integrated team and into their own specialty pharmacy system. NCODA supports efforts to enhance the continuity of care at the physician level where we […]
read more
Summit Cancer Centers
March 12, 2019 |
Mission Statement: Summit Cancer Centers mission is to maintain and increase high quality, lower cost cancer services, and to work at peak efficiency through owning, managing and operating comprehensive community cancer care facilities; and to offer patients throughout the Northwest a broad array of integrated, multidisciplinary cancer care services. Locations: Spokane, Spokane Valley, Post Falls, Boise Practice Details: […]
read more
Senate Finance Committee meeting with Pharma CEO’s today, 2/26/19
February 26, 2019 |
NCODA is closely watching today’s hearing on the issue of drug pricing. We will see the CEOs from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co, Pfizer, and Sanofi (plus the head of J&J’s pharma division) debate drug prices with lawmakers at a time when major legislative reform seems to be looming. More
read more
Women & Infants Hospital (Rhode Island)
February 14, 2019 |
Mission Statement: Women & Infants Hospital, a teaching hospital of The Warren Alpert Medical School of Brown University, is committed to improving the health and well-being of women and infants and to providing our essential services regardless of ability to pay.
read more
Patient-Reported Outcomes: indicators for oncology drug-approvals
February 13, 2019 |
NCODA supports the principle that medications should improve the patient’s quality of life while simultaneously treating the disease. We will continue to follow these developments as our patient-centered approach reaches the heart of clinical trial design in the oncology space. Article here
read more
Rep. Doug Collins introduces legislation to lower drug costs
February 8, 2019 |
Former NCODA Keynote Speaker Doug Collins (R-Ga.) reintroduced legislation that would increase transparency in drug pricing while lowering costs for patients. Updates on H.R. 1035 The Prescription Drug Pricing Transparency Act and H.R. 1034 The Phair Pricing Act can be found here at NCODA as we continue to advocate for cancer patients. Read More
read more
CREATES Act revived in Congress
February 7, 2019 |
Lawmakers are pushing forward legislation that would allow biosimilar and generic competition to enter the market sooner, suggesting that this change will drive down drug prices for US patients. Read more
read more
Aspirin use in HCC and Ovarian Cancer
February 4, 2019 |
Recent meta-analysis reveals low-dose aspirin may reduce the risk of certain cancers. Read more here:
read more
Anthem will launch in-house PBM in second-quarter 2019
February 1, 2019 |
Health insurer Anthem is launching its in-house pharmacy benefit manager IngenioRx nine months earlier than planned in the second quarter of 2019. Anthem said Wednesday that it will exercise its rights to terminate its current PBM contract with Express Scripts on March 1 before it expires at the end of the year, due to Cigna […]
read more
HHS Proposal Reforms Drug Rebates to Reduce Patient Spending
February 1, 2019 |
NCODA supports the HHS proposal to increase PBM transparency and pass drug rebate savings on to the patients. This new agenda would help reverse the current model which financially incentivizes the plan or the PBM. NCODA will continue to advocate for this movement as well as other national initiatives that support improved outcomes for cancer patients. Stay tuned […]
read more
Patient Adherence, a Challenge of Oral Chemotherapy
January 22, 2019 |
Chemotherapy once meant: An extended series of visits to a treatment center, Where the patient would be hooked up to an IV, often for hours, and infused with a heavy dose of anticancer drugs and supportive care medicines, All while being constantly monitored by healthcare professionals. Nowadays, that same process often can be accomplished by […]
read more
The Benefits of Medically Integrated Dispensing for Cancer Drugs
January 22, 2019 |
Although oral chemotherapy has dramatically changed the face of cancer treatment, how the drugs are dispensed can be nearly as important as the drugs themselves. “It’s one thing to prescribe an oral medicine for a patient,” said Guri K. Doshi, MD, a urinary and prostate cancer specialist with Texas Oncology, the state’s largest cancer care […]
read more
Arizona Oncology
January 14, 2019 |
Mission Statement: HOPE. STRENGTH. LOVE. – Our commitment to patients Arizona Oncology (AO) is the largest group of medical professionals in Arizona devoted exclusively to cancer care. With over 60 practicing physicians, we serve patients at over 25 locations throughout Arizona, including Arrowhead, Chandler, Cottonwood, Deer Valley, Flagstaff, Glendale, Green Valley, Nogales, Phoenix, Prescott Valley, Rita […]
read more
Southern Oncology Specialists
December 19, 2018 |
Mission Statement: Southern Oncology Specialists strives to be the first choice for cancer care in our community by being committed to providing evidence based, high quality, compassionate care for all individuals and their families who are affected by cancer.
read more
Simmons Cancer Institute at SIU Medicine
November 6, 2018 |
Mission Statement: The mission of SCI is to serve the people of central and southern Illinois by addressing their present and future cancer care needs through medical education, biomedical research, patient care and community service.
read more
NCODA Announces: Oncology Pharmacy Technician Association (OPTA)
October 23, 2018 |
For Immediate Release October 2018 National Community Oncology Dispensing Association, Inc. (NCODA) Announces Oncology Pharmacy Technician Association (OPTA) Cazenovia, NY – The National Community Oncology Dispensing Association, Inc. (NCODA) Executive Council is pleased to announce the establishment of the Oncology Pharmacy Technician Association (OPTA), the first professional association dedicated to supporting and encouraging the professional […]
read more
Texas Oncology
October 12, 2018 |
Mission Statement: Texas Oncology was founded in 1986 by a forward-thinking group of physicians who shared a vision to chart their own course. They believed there was a better way to provide cancer care. Together, they made community-based cancer treatment a reality. We’ve never strayed from our core mission to bring hope and a better […]
read more
Directions in Oncology Pharmacy®
October 2, 2018 |
Directions in Oncology Pharmacy® Saturday, November 10, 2018 Crowne Plaza Times Square Manhattan New York, New York Directions in Oncology Pharmacy® is a regional meeting hosted by Pharmacy Times Continuing Education™ positioned to offer education for clinical specialists, infusion staff, and specialty pharmacists. The mission of Directions in Oncology Pharmacy® is to provide practical, live […]
read more
Financial impact from in-office dispensing of oral chemotherapy
September 25, 2018 |
Authors: Anna Howard, Julia Kerr, Monica McLain, Jessie Modlin Oral chemotherapy agents are being prescribed more frequently in many cancer types. In-office dispensing of oral chemotherapy agents has demonstrated clinical benefits and also shown financial benefit to third-party payers. A previous publication estimated over $200,000 in cost savings annually from in-office dispensing solely from medications […]
read more
Dr Ali McBride: Addressing Adherence Issues With Patient Education
September 25, 2018 |
Oncology Nurse Navigators: Putting the Value in Value-Based Payment Models Lani M. Alison, BSN, MS-HCQ, PCMH CCE Oncology nurse navigators provide the “constant” in what seem to be undulating waves of changes to workflows, the adoption of new technology, the near-weekly onslaught of new drugs, and the need to ensure every nuance of documentation is […]
read more
The Medicare Patient’s Journey: Finding Financial Assistance for Prescription Medications
September 25, 2018 |
PAN New Infographic Spotlight: The Medicare Patient’s Journey—Finding Financial Assistance for Prescription Medications When a patient is diagnosed with a serious, chronic or life-threatening illness, the costs of treatment can be daunting—especially for those living on fixed incomes. Our latest infographic illustrates the journey of Mary, a fictional Medicare patient who searches for financial assistance […]
read more
Venetoclax (Venclexta®) Risk Stratification, Dosing, and Dispensing Procedure
September 22, 2018 |
Written By: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch Download Here Description: Venetoclax therapy requires particular parameters be closely followed to ensure optimal patient outcomes. This PQI will review appropriate risk stratification, dosing, and dispensing procedures. These risk stratifications create special challenges for the dispensing of venetoclax. Some medium-risk and all high-risk patients may require […]
read more
American Society of Clinical Oncology Position Statement: Pharmacy Benefit Managers and Their Impact on Cancer Care
September 6, 2018 |
The purpose of this ASCO Position Statement is to provide a summary of issues our members have raised about the role of PBMs in oncology, to share questions that have surfaced about PBM practices and their impact on physicians and patients, to assert ASCO’s immediate position on key issues, and to highlight areas of concern […]
read more
Smilow Cancer Hospital – Yale New Haven Health
September 4, 2018 |
Mission Statement: The mission of the Department of Pharmacy is to provide high value, patient-centered care. We will promote best practices that drive safe, effective, and timely medication therapy through all transitions of care. We will cultivate collaboration, innovation, education and career growth through employee engagement and practice advancement initiatives.
read more
Billings Clinic Cancer Center
August 10, 2018 |
Mission Statement: Billings Clinic Cancer Center Mission: To provide leading-edge care for patients and their families. Billings Clinic Cancer Center Vision: To be nationally recognized for premier cancer care and the first choice for patients, their families, and referring providers. Billings Clinic Cancer Center Core Values: Optimism: We believe in creating an environment of optimism […]
read more
Missouri Cancer Associates
August 10, 2018 |
Mission Statement: Our Family. Caring for Yours. We’ll be there every step of the way. Our physicians and staff are committed to providing friendly, professional, patient-centered care with dignity and respect for all. Missouri Cancer Associates is a full service medical and radiation oncology and hematology practice made up of 14 physicians in Columbia and […]
read more
Memorial Cancer Institute
August 10, 2018 |
Mission Statement: Memorial Healthcare System’s mission is to heal the body, mind, and spirit of all those we touch. Our vision is that The Memorial Cancer Institute (MCI) is the preeminent cancer center in South Florida and have national and international recognition in an effort to treat and prevent cancer.
read more
Bassett Healthcare Network Bassett Medical Center
June 22, 2018 |
Mission Statement: Bassett Medical Center is a part of Bassett Healthcare Network, a healthcare system that strives to provide excellence in healthcare to rural communities across eight counties in central New York. Bassett Medical Center is an academic medical center that exists to offer a continuum of care for our patients in all service lines, […]
read more
Helping Patients Faced with CoPay Accumulator Changes
June 20, 2018 |
(Excerpt from drugchannels.net) Patients today are being asked to pay a significant share of prescription costs for more-expensive specialty drugs, because of high coinsurance amounts. Many patients also face a deductible for their prescriptions.These are either a combined medical-pharmacy benefit deductible or an annual prescription drug deductible that was separate from any general annual deductible. […]
read more
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil)
June 16, 2018 |
PRINCETON, N.J., June 7, 2018 – Taiho Oncology, Inc. today announced that, in an effort to further support access for patients and their LONSURF® treatment, the co-pay for all dose strengths of LONSURF has been reduced from $30 to $0 per treatment cycle. The co-pay reduction, which took effect on May 1, 2018, is available […]
read more
Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
June 5, 2018 |
RealGiDo study results showed median time on treatment and time to progression of 18.7 and 20.8 months, respectively, were not impacted by dose modifications with Gilotrif® (afatinib) as first-line therapyGilotrif safety profile observed in real-world setting showed that there were no new safety signals Ridgefield, Conn., May 31, 2018 – Boehringer Ingelheim today announced results […]
read more
ASCO Selects NCODA Abstract for Publication: Cost Avoidance & Waste Tracker
May 27, 2018 |
Out of 6,400+ total scientific abstracts, the American Society of Clinical Oncology selected an NCODA abstract for online publication for the 2018 ASCO Annual Meeting. Through the abstract titled: Cost avoidance through the medically integrated dispensary (MID) for oral chemotherapy: Utilizing the NCODA cost avoidance and waste tracker, we were able to present collective intervention […]
read more
New England Cancer Specialists
May 13, 2018 |
Mission Statement: New England Cancer Specialists (NECS) goal is our patients best outcomes. We strive to make life better for patients with cancer and blood disorders. Our core values are commitment, quality, respect, accountability, integrity, and innovation.
read more
Hematology Oncology Associates of Central New York
May 13, 2018 |
MISSION STATEMENT The Mission of HOA is to provide the highest level of quality care in a healing environment for the mind, body and spirit of patients dealing with cancer and blood disorders. Our goal is to offer the highest level, state of the art technology and treatments, while meeting the emotional needs of our […]
read more
Joliet Oncology-Hematology Associates, Ltd. And Presence Cancer Care
May 13, 2018 |
MISSION STATEMENT/PHILOSOPHY: Joliet Oncology-Hematology Associates, Ltd. strives to continually improve the quality of life of our cancer patients; to provide patients with the highest quality of cancer care in an open supportive and compassionate environment;
read more
Tri-County Hematology Oncology Associates
May 10, 2018 |
Mission Statement: Our promise is a quality-driven service, and our aim is to ensure affordable access to our patients.
read more
NCODA Member Practice Goes Live with Medically Integrated Dispensary
April 26, 2018 |
Congratulations to NCODA member Gina Wertz, PharmD as her practice, Nebraska Hematology Oncology (NHO), launched their first medically integrated dispensary (MID) on Tuesday, April 17th, 2018.
read more
Patient Care Provider and Patient Burdens of Obtaining Oral Anticancer Medications
April 26, 2018 |
Oral anticancer medications are frequently used to treat patients with cancer. Dr. Daniel Geynisman and his team found significant time and energy burdens for clinic staff and patients in obtaining these drugs. Read more here.
read more
With the Oncology Care Model, “Everyone Has to Be Engaged,” Including Patients
April 24, 2018 |
American Journal of Managed Care – A generation ago, doctors made decisions, and everyone else adapted. The rise of patient-centered care has changed the game, making medicine a team effort, in which the physician collaborates with nurses, social workers, nutritionists, and other specialists. Most of all, physicians seek input from patients themselves. This is especially true […]
read more
Provider and Patient Burdens of Obtaining Oral Anticancer Medications
April 21, 2018 |
The American Journal of Managed Care > April 2018 – Oral anticancer medications are frequently used to treat patients with cancer. We found significant time and energy burdens for clinic staff and patients in obtaining these drugs. …. As payers and healthcare providers examine methods for quality improvement, they should consider improved processes to facilitate […]
read more
NCODA Members in Action
April 20, 2018 |
Chris Kepinski speaking at AJMC’s Institute for Value-Based Medicine NCODA member Chris Kepinski, clinical oncology pharmacy manager for Southern Oncology Specialists in North Carolina, recently spoke on a national panel regarding advancing quality in oncology care as part of the Institute for Value-Based Medicine, a new initiative of The American Journal of Managed Care. Read entire article in […]
read more
Designing Best Practices to Better Manage Patients on Oral Cancer Medications
April 19, 2018 |
This article in the AJMC discusses the positive quality interventions space within oncology dispensing. NCODA member Laura Joszt, 2018 NCODA Spring Forum attendee, explains NCODA’s efforts to improve patient care with best practices. Positive quality interventions are part of a nationwide effort to standardize and improve oncology dispensing practices. They are best practices that are meant […]
read more
Pacific Shores Medical Group
April 19, 2018 |
MISSION STATEMENT A Private Hematology and Oncology Specialty Practice offering exceptional care to each of our patients’ individual hematology and oncology specific needs.
read more
Abemaciclib effective as initial therapy for certain women with advanced breast cancer
April 18, 2018 |
The addition of abemaciclib (Verzenio) to initial treatment with a nonsteroidal aromatase inhibitor appeared effective for women with hormone receptor-positive, HER-2-negative advanced breast cancer, according to results of the double-blind, phase 3 MONARCH 3 study presented at American Association for Cancer Research Annual Meeting. Read More Here
read more
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
April 17, 2018 |
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced on 4/17/18 that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oral oncology drug candidate ARQ 087 (derazantinib), which targets the fibroblast growth factor receptor (FGFR) family of kinases. Read More Here
read more
Oral Chemotherapy Education Makes Impact at Texas Oncology Stakeholder Meeting
April 16, 2018 |
Members of Texas Oncology1, an independent, physician-led practice, were recently introduced to Oral Chemotherapy Education (OCE). OCE was conceived by the National Community Oncology Dispensing Association, Inc. (NCODA)2 as a resource to provide information about oral chemotherapy drugs and their side effects to both cancer patients and caregivers. OCE sheets are written with the needs of cancer […]
read more
Nominations Open for Living the Mission Award
April 2, 2018 |
The NCODA Living the Mission Award was established to recognize those member practitioners who exemplify the mission and values of NCODA in its quest to advance the value of dispensing practices for community oncology physicians and deliver positive outcomes through collaboration with all stakeholders involved in the care of oncology patients.
read more
Texas Oncology Receives PBMI 2018 Excellence Award
April 1, 2018 |
Excellence in Contributing to Care Management Strategies NCODA member practice Texas Oncology was awarded a PBMI 2018 Excellence Award, demonstrating excellence in contributing to Care Management Strategies for quality improvement with the Medically Integrated Pharmacy Care Model. NCODA Chair Jim Schwartz, RPh, Executive Director, Pharmacy Operations of Texas Oncology, received the award and said “We have been […]
read more
Oncology Nurse Navigators: Putting the Value in Value-Based Payment Models
March 30, 2018 |
Oncology nurse navigators provide the “constant” in what seem to be undulating waves of changes to workflows, the adoption of new technology, the near-weekly onslaught of new drugs, and the need to ensure every nuance of documentation is entered in discrete fields in electronic health records so the practice meets reporting requirements. Read more here.
read more
Copay Accumulators: Costly Consequences of a New Cost-Shifting Pharmacy Benefit
March 28, 2018 |
Accumulator programs target specialty drugs for which a manufacturer provides copayment assistance. Unlike conventional benefit designs, the manufacturer’s payments no longer count toward a patient’s deductible or out-of-pocket maximum. Plan sponsors (employers and health plans) will save big money because accumulators shift a majority of drug costs to patients and manufacturers. Accumulator programs will further lower […]
read more
New “Let’s Talk About Cost” Ads Highlight How Copay Accumulator Programs Leave Patients Financially Exposed
March 26, 2018 |
The Pharmaceutical Research and Manufacturers of America (PhRMA) recently unveiled new advertisements as part of its “Let’s Talk About Cost” campaign highlighting how the use of copay accumulator programs by insurance companies and other middlemen could result in patients facing thousands of dollars in unexpected medical costs. These programs block the copay coupons biopharmaceutical companies […]
read more
The Ghosh Center for Oncology & Hematology
March 22, 2018 |
Mission Statement Dr. Chirantan Ghosh founded The Ghosh Center with the philosophy of putting the interests of patients first and providing the highest quality of care with compassion and professionalism. Our core philosophy is that patients come first. We stand by the principles: Beneficence: doing good for our patients Nonmaleficence: do no harm Justice: treating patients with […]
read more
Cancer Partners of Nebraska
March 22, 2018 |
Mission Statement Cancer Partners of Nebraska provides comprehensive cancer care in Lincoln and the surrounding areas, combining advanced medical oncology, radiation oncology and pharmacy services.
read more
Coalition to Improve Access to Cancer Care (CIACC)
March 20, 2018 |
Outdated Cost-Sharing Policies Limit Patients’ Access to New Lifesaving Drugs Insurers do not offer comparable cost-sharing for many newer medicines administered by patients, including pills taken orally. Instead, most of those treatments are covered by a plan’s prescription benefit, which often require patients to pay much more out-of-pocket.
read more
Physician Dispensing – Adding value to patients and the practice
March 10, 2018 |
Oral oncolytics are serious medications prescribed to help patients with serious ailments. Patients and providers should fully understand and appreciate the risks and benefits before an oral oncolytic is prescribed. Today’s increasingly competitive oncology marketplace coupled with the tremendous increase in the number of FDA-approved (and pending) oral oncolytics has created a unique opportunity for […]
read more
When Things Unexpectedly Work Out
March 10, 2018 |
Number 65 Demonstrates Leadership Daniel Olszta, Joliet Oncology Hematology Associates, delivers on the National Community Oncology Dispensing Association’s mission… Passion for Patients. This article poignantly describes one mans’ battle with the current healthcare system. It was written in October 2017 by former Joliet, IL Herald-News reporter and editor Bill Wimbiscus. He can be reached at […]
read more
Better Care for Cancer Patients Motivates NCODA Members
March 7, 2018 |
Oncologists, Nurses, Pharmacy Technicians, Pharmacists, and Other Professionals Attend 2nd Annual Forum in Dallas The National Community Oncology Dispensing Association, Inc (NCODA) welcomed 165 oncology healthcare professionals representing more than 100 practices to its second annual NCODA Forum in Dallas, TX, March 1-3. A diverse group of professionals, including nurses, pharmacists, pharmacy techs, oncologists, administrators, […]
read more
Utah Cancer Specialists
February 22, 2018 |
MISSION STATEMENT/PHILOSOPHY The physicians, staff and management of Utah Cancer Specialists are dedicated to the diagnosis, treatment and management of all forms of cancer and blood related diseases. UCS is dedicated to helping people with these diseases achieve optimum health and quality of life through excellence in the delivery of compassionate medical care. UCS understands […]
read more
Passionate Financial Support – An Antidote for Financial Toxicity
February 1, 2018 |
Financial toxicity has become an urgent issue in the field of oncology due to the ever-growing number of patients having difficulty paying for their complex oncolytic treatments. This financial toxicity can lead to a decrease in adherence to cancer therapy. In January 2013 Hematology-Oncology Associates of Central New York (HOACNY), East Syracuse, N.Y., made the […]
read more
Virginia Cancer Specialists
January 22, 2018 |
Mission Statement Meeting and exceeding the needs of our patients is our primary goal. We recognize that each patient is an individual with unique needs. Our staff is dedicated to the fight against cancer and providing A New Way of Caring.
read more
An Innovative Platform for Oncology Practice Collaboration
October 30, 2017 |
By Joshua Nubla, PharmD; Neal Dave, PharmD; and Michael Reff, RPh, MBA An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care. Care for patients in the oncology setting is extremely diverse and complex. Management of the many distinct oral […]
read more
Letter from Congress: Ensuring Rebates and Discounts in Medicare Part D Help Reduce Patient OOP Costs
October 12, 2017 |
A letter from members of the U.S. Congress urging the U.S. Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid Services (CMS) to "work within existing authority to ensure Medicare Part D plan sponsors dedicate a meaningful share of negotiated rebates, discounts, and other fees to reduce Part D patients’ out-of […]
read more
OncLive® Expands Strategic Alliance Partnership Program With the National Community Oncology Dispensing Association
August 16, 2017 |
The collaboration aims to spread awareness of the growing need for dispensing cancer clinics CRANBURY, N.J.–(BUSINESS WIRE)–OncLive®, a leading digital provider of resources and information to oncology professionals, has teamed up with the National Community Oncology Dispensing Association (NCODA) through its Strategic Alliance Partnership (SAP) program. “Teaming up with the National Community Oncology Dispensing Association […]
read more
EGFR Inhibitors
April 11, 2017 |
Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here For patients with Non‐Small Cell Lung Cancer (NSCLC) that have sensitizing epidermal growth factor receptor (EGFR) mutations (most commonly exon 19 deletions or exon 21 L858R mutations) appropriate for first‐line treatment with an EGFR inhibitor, osimertinib (Tagrisso) has a clear progression free survival […]
read more
Chronic Lymphocytic Leukemia with Del17p
April 11, 2017 |
Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here Description: Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis. The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse. Testing rates at diagnosis and especially relapse are low. Venetoclax is […]
read more
DIRs: PBMs Pay Less Each Year While Prices Go Up
March 20, 2017 |
David Stanley recently contributed in the Modern Medicine Networking on how, "PBMs Pay Less Each Year While Prices Go Up". "Most of you are familiar with Medicare Part D direct and indirect remuneration (DIR) fees and know them as just another headache that comes along with your PBM contract. In a nutshell, when a DIR […]
read more
Update Patient Survey (English & Spanish)
March 15, 2017 |
NCODA has uploaded the updated patient survey in both English and Spanish in the member portal. Click here for English version. Click here for Spanish version.
read more
NCODA Spring Forum Agenda
February 22, 2017 |
This year’s Spring Summit in Chicago on March 2nd – 4th will cover a variety of topics such as: Sharing Value: NCODA Activities, Tools, Goals, ResourcesDefining EffectivenessAudits – Let’s hear from the auditorsIOD Accounting – Making Sense of the CentsMACRA/MIPS – What it means to you! Sybil GreenThe Problems with SPs and PBMs! War stories […]
read more
Implementing Oral Oncolytics: Steps to Success
November 30, 2016 |
As the use of oral oncolytics increases, cancer programs face a number of challenges to ensure high-quality care for cancer patients. There are significant variations in how cancer programs are treating patients with oral oncolytics. Arizona Oncology, a founding member of NCODA, is highlighted within:
read more
Big victory for Oncology Patients! – CVS pulls back on closing out in office dispensing.
October 31, 2016 |
Syracuse, NY, October 31, 2016 – NCODA (National Community Oncology Dispensing Association, Inc.) would like to highlight a major victory in the treatment landscape for oncology patients. On Thursday, October 27, CVS Health announced it had reversed its decision to limit Medicare Part D access away from oncology practices with in office dispensing as of […]
read more
PIF: Utah Cancer Specialists
June 1, 2016 |
MISSION STATEMENT/PHILOPSOPHY: The physicians, staff and management of Utah Cancer Specialists are dedicated to the diagnosis, treatment and management of all forms of cancer and blood related diseases. UCS is dedicated to helping people with these diseases achieve optimum health and quality of life through excellence in the delivery of compassionate medical care. UCS understands […]
read more
Practice in Focus: Virginia Cancer Specialist (VCS)
May 14, 2016 |
Mission Statement: Meeting and exceeding the needs of our patients is our primary goal. We recognize that each patient is an individual with unique needs. Our staff is dedicated to the fight against cancer and providing A New Way of Caring. Locations: Virginia Cancer Specialists has locations in Fairfax, Alexandria, Arlington, Fair Oaks, Gainesville, Loudon, […]
read more
NCODA Payor Update!
May 11, 2016 |
NCODA practices have successfully collaborated with another regional payor for the ability to go beyond the first fill! That brings the number of payers that have now collaborated with NCODA practices up to four! Several NCODA practices are currently in payor discussions!
read more
Waste in Cancer Drugs Costs $3 Billion a Year, a Study Says
May 11, 2016 |
WASHINGTON — The federal Medicare program and private health insurers waste nearly $3 billion every year buying cancer medicines that are thrown out because many drug makers distribute the drugs only in vials that hold too much for most patients, a group of cancer researchers has found. Click here for the New York Times Article… […]
read more
ONS:Edge White Paper: How to Overcome Adherence Challenges in Patients Taking Oral Therapy for mCRC
March 3, 2016 |
Oral oncolytic regimens have many benefits; however, patients can encounter barriers (e.g., institutional, socioeconomic, treatment) that can hinder their ability to take their medication as prescribed. Patients with metastatic colorectal cancer (mCRC) face complex dosing schedules that challenge adherence. When patients take oral therapies at home, healthcare professionals (HCPs) can use tools to empower their […]
read more
Antiemesis Prophylaxis Remains Inadequate
March 2, 2016 |
Approximately 40% of patients treated with anthracyclines are still not receiving National Comprehensive Cancer Network (NCCN) guideline–adherent prophylaxis for chemotherapy-induced vomiting. In most cases, guideline nonadherence was secondary to the lack of a neurokinin 1 (NK1) antagonist. Patients on highly emetogenic chemotherapy should receive prophylaxis in the form of a 5-HT3 antagonist in combination with […]
read more
Medicines in Development for Cancer
March 1, 2016 |
A REPORT ON CANCER More Than 800 Medicines and Vaccines in Clinical Testing for Cancer Offer New Hope to Patients In recent decades, tremendous – almost previously unthinkable – progress has been made in the fight against cancer. Advances in molecular and genomic research have revealed underlying complexities and provided insights into cancer, which we […]
read more
Iowa Teen Can’t Get Chemotherapy Drug Due to CVS Issue
January 26, 2016 |
A Council Bluffs family is furious. Their daughter is battling cancer. She is on a very strict drug maintenance program.When they went to pick up her chemotherapy drugs, they ran into one hurdle after another. "She asked me if she was going to die. That was the hardest," said Makayla Umphreys, Gracie’s mom. Click here […]
read more
NCODA’s Positive Quality Interventions: Breast Cancer
May 5, 2015 |
Description of PQI: Identify metastatic breast cancer patients appropriate for treatment with Palbociclib (Ibrance) therapy. Background: Palbociclib is a cyclin-dependent kinase 4/6 inhibitor indicated for initial endocrine-based therapy for postmenopausal women with ER+, HER2 negative metastatic breast cancer. Palbociclib is given in combination with the aromatase inhibitor Letrozole. An increase in progression free survival (PFS) […]
read more
Specialty Pharmacies Proliferate
May 3, 2015 |
NCODA’s View: This article highlights some of the challenges and issues that exist when you separate patients from the care and services they require. Cancer patients can be particular affected by this fragmentation and will benefit greatly by the expertise and capability of receiving their medications from their oncologist with a dedicated dispensing department. Having […]
read more
What Is a Navigator?
May 2, 2015 |
NCODA’s View: Proper handling and disposal of hazardous drugs is important. Dispensing practices can have a major impact in the education of patients and caregivers to help minimize exposure to these potentially harmful medications. The Ins and Outs Article – Click here to read more. TOP – May 2015, Vol 8, No 2 – CONFERENCE […]
read more
NCODA – Celebrating 1 year…success builds success…continuing to re-define the patient-centered model for the optimal management of oral cancer drug therapy.
April 24, 2015 |
April 2015 marks the one-year anniversary for the beginning of National Community Oncology Dispensing Association, Inc. (NCODA). Recognizing the growing separation between direct patient oversight and delivery of therapy, a group of dedicated pharmacists from New York gathered together to reverse the trend. Believing the best place for quality patient care lies with the treating […]
read more
NCODA – Leading a new standard in optimizing quality patient care to cancer patients receiving oral therapy.
March 20, 2015 |
March 19, 2015 (Syracuse, NY) – The ever changing environment of new treatment options for cancer patients is rapidly moving to a mix of intravenous and oral therapies. The increase in oral treatment options has led to many challenges in the current model of obtaining and delivering quality patient care. The National Community Oncology Dispensing […]
read more
RESOURCES
Cost Avoidance Waste Tracker
Positive Quality Interventions
PQI in Action
OCE Sheets
IVE Sheets
Treatment Support Kits
PQI Podcast
Members
Member Resources
OPTA
Committees
Member Login
Events
Webinars
Spring Forum
Oncology Institute
PSO Annual Meeting
Fall Summit
315-655-4640
P.O. Box 468
Cazenovia, NY 13035
